WO2000020602A2

WO2000020602A2 - Delta 6 and delta 12 desaturases and modified fatty acid biosynthesis and products produced therefrom

Info

Publication number: WO2000020602A2
Application number: PCT/US1999/022686
Authority: WO
Inventors: Pradip Mukerji; Yung-Sheng Huang; Jennifer M. Parker-Barnes; Tapas Das
Original assignee: Abbott Laboratories
Priority date: 1998-10-05
Filing date: 1999-09-29
Publication date: 2000-04-13
Also published as: AU1097900A; WO2000020602A3

Abstract

The present invention relates to fatty acid desaturases able to catalyze the conversion of oleic acid to linoleic acid, linoleic acid to η-linolenic acid, or of alpha-linolenic acid to stearidonic acid. Nucleic acid sequences encoding desaturases, purified desaturases, antibodies directed to the desaturases, nucleic acid sequences which hybridize thereto, DNA constructs comprising a desaturase gene, and recombinant host microorganism or animal expressing increased levels of a desaturase are described. Methods for desaturating a fatty acid and for producing a desaturated fatty acid by expressing increased levels of a desaturase are disclosed. Methods of producing transgenic oil in microorganisms are disclosed. Methods of purifying the oils and preparing the oils for food products are also disclosed. Fatty acids, and oils containing them, which have been desaturated by a desaturase produced by recombinant host microorganisms or animals are provided. Pharmaceutical compositions, infant formulas or dietary supplements containing fatty acids which have been desaturated by a desaturase produced by a recombinant host microorganism or animal also are described.

Description

DELTA 6 AND DELTA 12 DESATURASES AND MODIFIED FATTY ACID BIOSYNTHESIS AND PRODUCTS PRODUCED THEREFROM

INTRODUCTION

Field of the Invention

This invention relates to modulating levels of enzymes and/or enzyme components relating to production of long chain polyunsaturated fatty acids (PUFAs) and Δ6 and Δ12 desaturases in insects or animals.

Background Two main families of polyunsaturated fatty acids (PUFAs) are the cc>3 fatty acids, exemplified by eicosapentaenoic acid (EPA), and the ω6 fatty acids, exemplified by arachidonic acid (ARA). PUFAs are important components of the plasma membrane of the cell, where they may be found in such forms as phospholipids. PUFAs are necessary for proper development, particularly in the developing infant brain, and for tissue formation and repair. PUFAs also serve as precursors to other molecules of importance in human beings and animals, including the prostacyclins, eicosanoids, leukotrienes and prostaglandins. Four major long chain PUFAs of importance include docosahexaenoic acid (DHA) and EPA, which are primarily found in different types of fish oil, γ-linolenic acid (GLA), which is found in the seeds of a number of plants, including evening primrose (Oenothera biennis), borage (Borago officinalis) and black currants (Ribes nigrum), and stearidonic acid (SDA), which is found in marine oils and plant seeds. Both GLA and another important long chain PUFA, arachidonic acid (ARA), are found in filamentous fungi. ARA can be purified from animal tissues including liver and adrenal gland. GLA, ARA, EPA and

SDA are themselves, or are dietary precursors to, important long chain fatty acids involved in prostaglandin synthesis, in treatment of heart disease, and in development of brain tissue.

For DHA, a number of sources exist for commercial production including a variety of marine organisms, oils obtained from cold water marine fish, and egg yolk fractions. For ARA, microorganisms including the genera Mortierella, Entomophthora, Phytium and Porphyridium can be used for commercial production. Commercial sources of SDA include the genera Trichodesma and Echiu . Commercial sources of GLA include evening primrose, black currants and borage. However, there are several disadvantages associated with commercial production of PUFAs from natural sources. Natural sources of PUFAs, such as animals and plants, tend to have highly heterogeneous oil compositions. The oils obtained from these sources therefore can require extensive purification to separate out one or more desired PUFAs or to produce an oil which is enriched in one or more PUFA. Natural sources also are subject to uncontrollable fluctuations in availability. Fish stocks may undergo natural variation or may be depleted by overfishing. Fish oils have unpleasant tastes and odors, which may be impossible to economically separate from the desired product, and can render such products unacceptable as food supplements. Animal oils, and particularly fish oils, can accumulate environmental pollutants. Weather and disease can cause fluctuation in yields from both fish and plant sources. Cropland available for production of alternate oil-producing crops is subject to competition from the steady expansion of human populations and the associated increased need for food production on the remaining arable land. Crops which do produce PUFAs, such as borage, have not been adapted to commercial growth and may not perform well in monoculture. Growth of such crops is thus not economically competitive where more profitable and better established crops can be grown. Large scale fermentation of organisms such as Mortierella is also expensive. Natural animal tissues contain low amounts of ARA and are difficult to process.

Microorganisms such as Porphyridium and Mortierella are difficult to cultivate on a commercial scale.

Dietary supplements and pharmaceutical formulations containing PUFAs can retain the disadvantages of the PUFA source. Supplements such as fish oil capsules can contain low levels of the particular desired component and thus require large dosages. High dosages result in ingestion of high levels of undesired components, including contaminants. Unpleasant tastes and odors of the supplements can make such regimens undesirable, and may inhibit compliance by the patient. Care must be taken in providing fatty acid supplements, as overaddition may result in suppression of endogenous biosynthetic pathways and lead to competition with other necessary fatty acids in various lipid fractions in vivo, leading to undesirable results. For example,

Eskimos having a diet high in ω3 fatty acids have an increased tendency to bleed (U.S. Pat. No. 4,874,603).

A number of enzymes are involved in PUFA biosynthesis. Linoleic acid (LA, 18:2 Δ9, 12) is produced from oleic acid (18:1 Δ9) by a Δ12-desaturase. GLA (18:3 Δ6, 9, 12) is produced from linolenic acid (LA, 18:2 Δ9, 12) by a

Δ6-desaturase. ARA (20:4 Δ5, 8, 11, 14) production from dihomo-γ -linolenic acid (DGLA, 20:3 Δ8, 11, 14) is catalyzed by a Δ5-desaturase. However, animals cannot desaturate beyond the Δ9 position and therefore cannot convert oleic acid (18:1 Δ9) into linolenic acid (18:2 Δ9, 12). Likewise, α-linolenic acid (ALA, 18:3 Δ9, 12, 15) cannot be synthesized by mammals. Other eukaryotes, including fungi and plants, have enzymes which desaturate at positions Δ12 and Δ15. The major poly-unsaturated fatty acids of animals therefore are either derived from diet and/or from desaturation and elongation of linolenic acid (18:2 Δ9, 12) or oc-linolenic acid (18:3 Δ9, 12, 15). Therefore it is of interest to obtain genetic material involved in PUFA biosynthesis from species that naturally produce these fatty acids and to express the isolated material in a microbial or animal system which can be manipulated to provide production of commercial quantities of one or more PUFAs. Thus there is a need for fatty acid desaturases, genes encoding them, and recombinant methods of producing them. A need further exists for oils containing higher relative proportions of and/or enriched in specific PUFAs. A need also exists for reliable economical methods of producing specific PUFAs.

In particular, there is a need to express Δ6, Δ9, Δ12 and Δ15 desaturases and PUFAs in a baculovirus expression system using cultured insect cells such as Spodoptera frugiperda (Sf9), army fall worm. The purified desaturases may be used for enzyme studies as well as antigens in polyclonal and monoclonal antibody production.

The lipid composition of Sf9 cells has been well characterized and are known to contain low proportions of polyunsaturated fatty acids. As such, production of PUFAs in insect cells would provide a good source of PURAs for use in various oils, nutritional supplements, cosmetic agents and the like.

SUMMARY OF THE INVENTION

Novel compositions and methods are provided for preparation of polyunsaturated long chain fatty acids. The compositions include nucleic acid encoding a Δ6- and Δ12- desaturase and/or polypeptides having Δ6- and/or Δ12- desaturase activity, the polypeptides, and probes isolating and detecting the same. The methods involve growing a host insect or animal expressing an introduced gene or genes encoding at least one desaturase, particularly a Δ6-, Δ9-, Δ12- or Δ15-desaturase. The methods also involve the use of antisense constructs or gene disruptions to decrease or eliminate the expression level of undesired desaturases. Regulation of expression of the desaturase polypeptide(s) provides for a relative increase in desired desaturated PUFAs as a result of altered concentrations of enzymes and substrates involved in PUFA biosynthesis. The invention finds use, for example, in the large scale production of GLA, DGLA, ARA, EPA, DHA and SDA.

The invention is also directed to methods of producing purified Δ6, Δ9, Δ12 or Δ15 desaturase in an insect cell culture system. The purified protein can be used as an antigen for the production of polyclonal and monoclonal antibodies. These antibodies find use in methods of purifying the Δ6, Δ9, Δ12 or Δ15 desaturase and in the methods of detecting levels of Δ6, Δ9, Δ12 or Δ15 desaturase polypeptide in complex solutions.

The purified Δ6, Δ9, Δ12 or Δ15 desaturase protein also finds use in studies of the Δ6, Δ9, Δ12 or Δ15 desaturase enzyme including X-ray diffraction studies for structure-function analysis. Once the purified protein has been studied in some detail, the enzyme can be modified by genetic engineering techniques to improve enzymatic activity and to alter substrate specificities.

In a preferred embodiment of the invention, an isolated nucleic acid comprising: a nucleotide sequence depicted in Figure 3A-E (SEQ ID NO: 1) or Figure 5A-D (SEQ ID NO: 3), a polypeptide encoded by a nucleotide sequence according Figure 3A-E (SEQ ID NO: 1) or Figure 5 A-D (SEQ ID NO: 3), and a purified or isolated polypeptide comprising an amino acid sequence depicted in Figure 3A-E (SEQ ID NO: 2) or Figure 5A-D (SEQ ID NO: 4). In another embodiment of the invention, provided is an isolated nucleic acid encoding a polypeptide having an amino acid sequence depicted in Figure 3A-E (SEQ ID

NO: 2) or Figure 5A-D (SEQ ID NO: 4).

Also provided is an isolated nucleic acid comprising a nucleotide sequence which encodes a polypeptide which desaturates a fatty acid molecule at carbon 6 or 12 from the carboxyl end, wherein said nucleotide sequence has an average A/T content of less than about 60%. In a preferred embodiment, the isolated nucleic acid is derived from a fungus, such as a fungus of the genus Mortierella. More preferred is a fungus of the species Mortierella alpina.

In another preferred embodiment of the invention, an isolated nucleic acid is provided wherein the nucleotide sequence of the nucleic acid is depicted in Figure 3A-E (SEQ ID NO: 1) or Figure 5A-D (SEQ ID NO: 3). The invention also provides an isolated or purified polypeptide which desaturates a fatty acid molecule at carbon 6 or 12 from the carboxyl end, wherein the polypeptide is a eukaryotic polypeptide or is derived from a eukaryotic polypeptide, where a preferred eukaryotic polypeptide is derived from a fungus. The present invention further includes a nucleic acid sequence which hybridizes to Figure 3A-E (SEQ ID NO: 1) or Figure 5A-D (SEQ ID NO: 3). Preferred is an isolated nucleic acid having a nucleotide sequence with at least about 50% homology to Figure 3A-E (SEQ ID NO: 1) or Figure 5 A-D (SEQ ID NO: 3). The invention also includes an isolated nucleic acid having a nucleotide sequence with at least about 50% homology to Figure 3A-E (SEQ

ID NO: 1) or Figure 5 A-D (SEQ ID NO: 3). In a preferred embodiment, the nucleic acid of the invention includes a nucleotide sequence which encodes an amino acid sequence depicted in Figure 3A-D (SEQ ID NO: 2) which is selected from the group consisting of amino acid residues 50-53, 39-43, 172- 176, 204-213, and 390-402. Also provided by the present invention is a nucleic acid construct comprising a nucleotide sequence depicted in a Figure 3A-E (SEQ ID NO: 1) or Figure 5A-D (SEQ ID NO: 3) linked to a heterologous nucleic acid. In another embodiment, a nucleic acid construct is provided which comprises a nucleotide sequence depicted in a Figure 3A-E (SEQ ID NO: 1) or Figure 5A- D (SEQ ID NO: 3) operably associated with an expression control sequence functional in a host cell. The host cell is either eukaryotic or prokaryotic. Preferred eukaryotic host cells are those selected from the group consisting of a mammalian cell, an insect cell, a fungal cell, and an algae cell. Preferred mammalian cells include an avian cell, a preferred fungal cell includes a yeast cell, and a preferred algae cell is a marine algae cell. Preferred prokaryotic cells include those selected from the group consisting of a bacteria, a cyanobacteria, cells which contain a bacteriophage, and/or a virus. The DNA sequence of the recombinant host cell preferably contains a promoter which is functional in the host cell, which promoter is preferably inducible. In a more preferred embodiment, the microbial cell is a fungal cell of the genus Mortierella, with a more preferred fungus is of the species Mortierella alpina.

In addition, the present invention provides a nucleic acid construct comprising a nucleotide sequence which encodes a polypeptide comprising an amino acid sequence which corresponds to or is complementary to an amino acid sequence depicted in Figure 3A-E (SEQ ID NO: 2) or Figure 5A-D (SEQ

ID NO: 4), wherein the nucleic acid is operably associated with an expression control sequence functional in a microbial cell, wherein the nucleotide sequence encodes a functionally active polypeptide which desaturates a fatty acid molecule at carbon 6 or carbon 12 from the carboxyl end of a fatty acid molecule. Another embodiment of the present invention is a nucleic acid construct comprising a nucleotide sequence which encodes a functionally active Δ6-desaturase having an amino acid sequence which corresponds to or is complementary to all of or a portion of an amino acid sequence depicted in a Figure 3A-E (SEQ ID NO: 2), wherein the nucleotide sequence is operably associated with a transcription control sequence functional in a host cell.

Yet another embodiment of the present invention is a nucleic acid construct comprising a nucleotide sequence which encodes a functionally active Δ12-desaturase having an amino acid sequence which corresponds to or is complementary to all of or a portion of an amino acid sequence depicted in a Figure 5A-D (SEQ ID NO: 4), wherein the nucleotide sequence is operably associated with a transcription control sequence functional in a host cell. The host cell, is either a eukaryotic or prokaryotic host cell. Preferred eukaryotic host cells are those selected from the group consisting of a mammalian cell, an insect cell, a fungal cell, and an algae cell. Preferred mammalian cells include an avian cell, a preferred fungal cell includes a yeast cell, and a preferred algae cell is a marine algae cell. Most preferred eukaryotic cells are insect cells; most preferably fall army worm cells Spodoptera frugiperda (Sf9 and Sf21 cells) and cabbag lopper moths Trichloplusia ni (Hi Five cells). Preferred prokaryotic cells include those selected from the group consisting of a bacteria, a cyanobacteria, cells which contain a bacteriophage, and/or a virus. The DNA sequence of the recombinant host cell preferably contains a promoter which is functional in the host cell and which preferably is inducible. A preferred recombinant host cell is a microbial cell such as a yeast cell, such as a Saccharomyces cell.

The present invention also provides a recombinant microbial cell comprising at least one copy of a nucleic acid which encodes a functionally active Mortierella alpina fatty acid desaturase having an amino acid sequence as depicted in Figure 3A-E (SEQ ID NO: 2), wherein the cell or a parent of the cell was transformed with a vector comprising said DNA sequence, and wherein the DNA sequence is operably associated with an expression control sequence. In a preferred embodiment, the cell is a microbial cell which is enriched in 18:2 fatty acids, particularly where the microbial cell is from a genus selected from the group consisting of a prokaryotic cell and eukaryotic cell. In another preferred embodiment, the microbial cell according to the invention includes an expression control sequence which is endogenous to the microbial cell.

Also provided by the present invention is a method for production of GLA in a host cell, where the method comprises growing a host culture having a plurality of host cells which contain one or more nucleic acids encoding a polypeptide which converts LA to GLA, wherein said one or more nucleic acids is operably associated with an expression control sequence, under conditions whereby said one or more nucleic acids are expressed, whereby GLA is produced in the host cell. In several preferred embodiments of the methods, the polypeptide employed in the method is a functionally active enzyme which desaturates a fatty acid molecule at carbon 6 from the carboxyl end of a fatty acid molecule; the said one or more nucleic acids is derived from a Mortierella alpina; the substrate for the polypeptide is exogenously supplied; the host cells are microbial cells; the microbial cells are yeast cells, such as Saccharomyces cells; and the growing conditions are inducible.

Also provided is an oil comprising one or more PUFA, wherein the amount of said one or more PUFAs is approximately 0.3-30% arachidonic acid (ARA), approximately 0.2-30% dihomo-γ-linolenic acid (DGLA), and approximately 0.2-30% γ-linoleic acid (GLA). A preferred oil of the invention is one in which the ratio of ARA:DGLA:GLA is approximately 1.0: 19.0:30 to

6.0:1.0:0.2. Another preferred embodiment of the invention is a pharmaceutical composition comprising the oils in a pharmaceutically acceptable carrier. Further provided is a nutritional composition comprising the oils of the invention. The nutritional compositions of the invention preferably are administered to a mammalian host parenterally or internally. A preferred composition of the invention for internal consumption is an infant formula. In a preferred embodiment, the nutritional compositions of the invention are in a liquid form or a solid form, and can be formulated in or as a dietary supplement, and the oils provided in encapsulated form. The oils of the invention can be free of particular components of other oils and can be derived from a microbial cell, such as a yeast cell. The present invention further provides a method for desaturating a fatty acid. In a preferred embodiment the method comprises culturing a recombinant microbial cell according to the invention under conditions suitable for expression of a polypeptide encoded by said nucleic acid, wherein the host cell further comprises a fatty acid substrate of said polypeptide. Also provided is a fatty acid desaturated by such a method, and an oil composition comprising a fatty acid produced according to the methods of the invention.

The present invention further includes a purified nucleotide sequence or polypeptide sequence that is substantially related or homologous to the nucleotide and peptide sequences presented in SEQ ID NO: 1 - SEQ ID NO:40.

The present invention is further directed to methods of using the sequences presented in SEQ ID NO: 1 to SEQ ID NO:40 as probes to identify related sequences, as components of expression systems and as components of systems useful for producing transgenic oil. The present invention is further directed to formulas, dietary supplements or dietary supplements in the form of a liquid or a solid containing the long chain fatty acids of the invention. These formulas and supplements may be administered to a human or an animal.

The formulas and supplements of the invention may further comprise at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, mono- and diglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, and other protein hydrolysates.

The formulas of the present invention may further include at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex; and at least one mineral selected from the group consisting of calcium, magnesium, zinc, manganese, sodium, potassium, phosphorus, copper, chloride, iodine, selenium, and iron.

The present invention is further directed to a method of treating a patient having a condition caused by insufficient intake or production of polyunsaturated fatty acids comprising administering to the patient a dietary substitute of the invention in an amount sufficient to effect treatment of the patient.

The present invention is further directed to cosmetic and pharmaceutical compositions of the material of the invention. The present invention is further directed to transgenic oils in pharmaceutically acceptable carriers. The present invention is further directed to nutritional supplements, cosmetic agents and infant formulae containing transgenic oils.

The present invention is further directed to a method for obtaining altered long chain polyunsaturated fatty acid biosynthesis comprising the steps of: growing a microbe having cells which contain a transgene which encodes a transgene expression product which desaturates a fatty acid molecule at carbon 6 or 12 from the carboxyl end of said fatty acid molecule, wherein the transgene is operably associated with an expression control sequence, under conditions whereby the transgene is expressed, whereby long chain polyunsaturated fatty acid biosynthesis in the cells is altered.

The present invention is further directed toward pharmaceutical compositions comprising at least one nutrient selected from the group consisting of a vitamin, a mineral, a carbohydrate, a sugar, an amino acid, a free fatty acid, a phospholipid, an antioxidant, and a phenolic compound.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows possible pathways for the synthesis of arachidonic acid (20:4 Δ5, 8, 11, 14) and stearidonic acid (18:4 Δ6, 9, 12, 15) from palmitic acid (Cι₆) from a variety of organisms, including algae, Mortierella and humans.

These PUFAs can serve as precursors to other molecules important for humans and other animals, including prostacyclins, leukotrienes, and prostaglandins, some of which are shown. Figure 2 shows possible pathways for production of PUFAs in addition to ARA, including EPA and DHA, again compiled from a variety of organisms.

Figure 3A-E shows the DNA sequence of the Mortierella alpina Δ6- desaturase and the deduced amino acid sequence: Figure 3A-E (SEQ ID NO 1 Δ6 DESATURASE cDNA)

Figure 3A-E (SEQ ID NO 2 Δ6 DESATURASE AMINO ACID)

Figure 4 shows an alignment of a portion of the Mortierella alpina Δ6- desaturase amino acid sequence with other related sequences.

Figure 5 A-D shows the DNA sequence of the Mortierella alpina Δ12- desaturase and the deduced amino acid sequence:

Figure 5A-D (SEQ ID NO 3 Δ12 DESATURASE cDNA)

Figure 5 A-D (SEQ ID NO 4 Δ12 DESATURASE AMINO ACID).

Figures 6A and 6B show the effect of different expression constructs on expression of GLA in yeast. Figures 7 A and 7B show the effect of host strain on GLA production.

Figures 8A and 8B show the effect of temperature on GLA production in S. cerevisiae strain SC334.

Figure 9 shows alignments of the protein sequence of the Ma 29 and contig 253538a. Figure 10 shows alignments of the protein sequence of Ma 524 and contig 253538a.

BRIEF DESCRIPTION OF THE SEQUENCE LISTINGS

SEQ ID NO: 1 shows the DNA sequence of the Mortierella alpina Δ6- desaturase. SEQ ID NO:2 shows the protein sequence of the Mortierella alpina Δ6- desaturase. SEQ ID NO:3 shows the DNA sequence of the Mortierella alpina Δ12- desaturase.

SEQ ID NO:4 shows the protein sequence of the Mortierella alpina Δ12-desaturase. SEQ ID NO:5-l 1 show various desaturase sequences.

SEQ ID NO: 13-18 show various PCR primer sequences.

SEQ ID NO: 19 and SEQ ID NO:20 show the nucleotide and amino acid sequence of a Dictyostelium discoideum desaturase.

SEQ ID NO:21 and SEQ ID NO:22 show the nucleotide and amino acid sequence of a Phaeodactylum tricornutum desaturase.

SEQ ID NO:23-26 show the nucleotide and deduced amino acid sequence of a Schizochytrium cDNA clone.

SEQ ID NO: 27-33 show nucleotide sequences for human desaturases.

SEQ ID NO:34 - SEQ ID NO:40 show peptide sequences for human desaturases.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

In order to ensure a complete understanding of the invention, the following definitions are provided:

Δ5-Desaturase: Δ5 desaturase is an enzyme which introduces a double bond between carbons 5 and 6 from the carboxyl end of a fatty acid molecule.

Δ6-Desaturase: Δ6-desaturase is an enzyme which introduces a double bond between carbons 6 and 7 from the carboxyl end of a fatty acid molecule.

Δ9-Desaturase: Δ9-desaturase is an enzyme which introduces a double bond between carbons 9 and 10 from the carboxyl end of a fatty acid molecule. Δl2-Desaturase: Δl2-desaturase is an enzyme which introduces a double bond between carbons 12 and 13 from the carboxyl end of a fatty acid molecule. Fatty Acids: Fatty acids are a class of compounds containing a long hydrocarbon chain and a terminal carboxylate group. Fatty acids include the following:

Taking into account these definitions, the present invention is directed to novel DNA sequences, DNA constructs, methods and compositions are provided which permit modification of the poly-unsaturated long chain fatty acid content of, for example, microbial cells or animals. Host cells are manipulated to express a sense or antisense transcript of a DNA encoding a polypeptide(s) which catalyzes the desaturation of a fatty acid. The substrate(s) for the expressed enzyme may be produced by the host cell or may be exogenously supplied. To achieve expression, the transformed DNA is operably associated with transcriptional and translational initiation and termination regulatory regions that are functional in the host cell. Constructs comprising the gene to be expressed can provide for integration into the genome of the host cell or can autonomously replicate in the host cell. For production of linoleic acid (LA), the expression cassettes generally used include a cassette which provides for Δ12-desaturase activity, particularly in a host cell which produces or can take up oleic acid (U.S. Patent No. 5,443,974). Production of LA also can be increased by providing an expression cassette for a Δ9- desaturase where that enzymatic activity is limiting. For production of ALA, the expression cassettes generally used include a cassette which provides for Δ15- or ω3 -desaturase activity, particularly in a host cell which produces or can take up LA. For production of GLA or SDA, the expression cassettes generally used include a cassette which provides for Δ6-desaturase activity, particularly in a host cell which produces or can take up LA or ALA, respectively. Production of ω6-type unsaturated fatty acids, such as LA or GLA, is favored in a host microorganism or animal which is incapable of producing ALA. The host ALA production can be removed, reduced and/or inhibited by inhibiting the activity of a Δ15- or ω3- type desaturase (see Figure 2). This can be accomplished by standard selection, providing an expression cassette for an antisense Δ15 or co3 transcript, by disrupting a target Δ15- or ω3 -desaturase gene through insertion, deletion, substitution of part or all of the target gene, or by adding an inhibitor of Δ15- or ω3-desaturase. Similarly, production of LA or ALA is favored in a microorganism or animal having Δ6-desaturase activity by providing an expression cassette for an antisense Δ6 transcript, by disrupting a Δ6-desaturase gene, or by use of a Δ6-desaturase inhibitor. INSECT CELL PRODUCTION OF FATTY ACIDS

Insect cell production of fatty acids and desaturases has several advantages over purification from natural sources such as fish or plants. Many insect cells are known with greatly simplified oil compositions compared with those of higher organisms, making purification of desired components easier.

Insect cell production is not subject to fluctuations caused by external variables such as weather and food supply. Insect cell produced lipids are substantially free of contamination by environmental pollutants. Additionally, microbes can provide PUFAs in particular forms which may have specific uses. Additionally, insect cell desaturase and lipid production can be manipulated by controlling culture conditions, notably by providing particular substrates for microbially expressed enzymes, or by addition of compounds which suppress undesired biochemical pathways. In addition to these advantages, production of fatty acids from recombinant microbes provides the ability to alter the naturally occurring microbial fatty acid profile by providing new synthetic pathways in the host or by suppressing undesired pathways, thereby increasing levels of desired PUFAs, or conjugated forms thereof, and decreasing levels of undesired PUFAs.

PRODUCTION OF FATTY ACIDS IN ANIMALS Production of fatty acids in animals also presents several advantages.

Expression of desaturase genes in animals can produce greatly increased levels of desired PUFAs in animal tissues, making recovery from those tissues more economical. For example, where the desired PUFAs are expressed in the breast milk of animals, methods of isolating PUFAs from animal milk are well established. In addition to providing a source for purification of desired

PUFAs, animal breast milk can be manipulated through expression of desaturase genes, either alone or in combination with other human genes, to provide animal milks substantially similar to human breast milk during the different stages of infant development. Humanized animal milks could serve as infant formulas where human nursing is impossible or undesired, or in cases of malnourishment or disease. Depending upon the host cell, the availability of substrate, and the desired end product(s), several polypeptides, particularly desaturases, are of interest. By "desaturase" is intended a polypeptide which can desaturate one or more fatty acids to produce a mono- or poly-unsaturated fatty acid or precursor thereof of interest. Of particular interest are polypeptides which can catalyze the conversion of stearic acid to oleic acid, of oleic acid to LA, of LA to ALA, of LA to GLA, or of ALA to SDA, which includes enzymes which desaturate at the Δ9, Δ12, (ω6), Δ15, (ω3) or Δ6 positions. By "polypeptide" is meant any chain of amino acids, regardless of length or post-translational modification, for example, glycosylation or phosphorylation. Considerations for choosing a specific polypeptide having desaturase activity include the pH optimum of the polypeptide, whether the polypeptide is a rate limiting enzyme or a component thereof, whether the desaturase used is essential for synthesis of a desired polyunsaturated fatty acid, and/or co-factors required by the polypeptide. The expressed polypeptide preferably has parameters compatible with the biochemical environment of its location in the host cell. For example, the polypeptide may have to compete for substrate with other enzymes in the host cell. Analyses of the K_m and specific activity of the polypeptide in question therefore are considered in determining the suitability of a given polypeptide for modifying PUFA production in a given host cell. The polypeptide used in a particular situation is one which can function under the conditions present in the intended host cell but otherwise can be any polypeptide having desaturase activity which has the desired characteristic of being capable of modifying the relative production of a desired PUFA. For production of linoleic acid from oleic acid, the DNA sequence used encodes a polypeptide having Δ12-desaturase activity. For production of GLA from linoleic acid, the DNA sequence used encodes a polypeptide having Δ6- desaturase activity. In particular instances, expression of Δ6-desaturase activity can be coupled with expression of Δ12-desaturase activity and the host cell can optionally be depleted of any Δ15-desaturase activity present, for example by providing a transcription cassette for production of antisense sequences to the Δ15-desaturase transcription product, by disrupting the Δ15-desaturase gene, or by using a host cell which naturally has, or has been mutated to have, low Δ15- desaturase activity. Inhibition of undesired desaturase pathways also can be accomplished through the use of specific desaturase inhibitors such as those described in U.S. Patent No. 4,778,630. Also, a host cell for Δ6-desaturase expression may have, or have been mutated to have, high Δ12-desaturase activity. The choice of combination of cassettes used depends in part on the PUFA profile and/or desaturase profile of the host cell. Where the host cell expresses Δ12-desaturase activity and lacks or is depleted in Δ15-desaturase activity, overexpression of Δ6-desaturase alone generally is sufficient to provide for enhanced GLA production. Where the host cell expresses Δ9-desaturase activity, expression of a Δ12- and a Δ6-desaturase can provide for enhanced GLA production. When Δ9-desaturase activity is absent or limiting, an expression cassette for Δ9-desaturase can be used. A scheme for the synthesis of arachidonic acid (20:4 Δ5, 8, 11, 14) from stearic acid (18:0) is shown in Figure 2. A key enzyme in this pathway is a Δ6-desaturase which converts the linoleic acid into γ-linolenic acid. Conversion of α-linolenic acid (ALA) to stearidonic acid by a Δ6-desaturase also is shown.

SOURCES OF POLYPEPTIDES HAVING DESATURASE ACTIVITY A source of polypeptides having desaturase activity and oligonucleotides encoding such polypeptides are organisms which produce a desired polyunsaturated fatty acid. As an example, microorganisms having an ability to produce GLA or ARA can be used as a source of Δ6- or Δ12- desaturase activity. Such microorganisms include, for example, those belonging to the genera Mortierella, Conidiobolus, Pythium, Phytophathora, Penicillium,

Porphyridium, Coidosporium, Mucor, Fusarium, Aspergillus, Rhodotorula, and Entomophthora. Within the genus Porphyridium, of particular interest is Porphyridium cruentum. Within the genus Mortierella, of particular interest are Mortierella elongata, Mortierella exigua, Mortierella hygrophila, Mortierella ramanniana, var. angulispora, and Mortierella alpina. Within the genus Mucor, of particular interest are Mucor circinelloides and Mucor javanicus. DNAs encoding desired desaturases can be identified in a variety of ways. As an example, a source of the desired desaturase, for example genomic or cDNA libraries from Mortierella, is screened with detectable enzymatically- or chemically-synthesized probes, which can be made from DNA, RNA, or non- naturally occurring nucleotides, or mixtures thereof. Probes may be enzymatically synthesized from DNAs of known desaturases for normal or reduced-stringency hybridization methods. Oligonucleotide probes also can be used to screen sources and can be based on sequences of known desaturases, including sequences conserved among known desaturases, or on peptide sequences obtained from the desired purified protein. Oligonucleotide probes based on amino acid sequences can be degenerate to encompass the degeneracy of the genetic code, or can be biased in favor of the preferred codons of the source organism. Oligonucleotides also can be used as primers for PCR from reverse transcribed mRNA from a known or suspected source; the PCR product can be the full length cDNA or can be used to generate a probe to obtain the desired full length cDNA. Alternatively, a desired protein can be entirely sequenced and total synthesis of a DNA encoding that polypeptide performed.

Once the desired genomic or cDNA has been isolated, it can be sequenced by known methods. It is recognized in the art that such methods are subject to errors, such that multiple sequencing of the same region is routine and is still expected to lead to measurable rates of mistakes in the resulting deduced sequence, particularly in regions having repeated domains, extensive secondary structure, or unusual base compositions, such as regions with high GC base content. When discrepancies arise, resequencing can be done and can employ special methods. Special methods can include altering sequencing conditions by using: different temperatures; different enzymes; proteins which alter the ability of oligonucleotides to form higher order structures; altered nucleotides such as LTP or methylated dGTP; different gel compositions, for example adding formamide; different primers or primers located at different distances from the problem region; or different templates such as single stranded DNAs.

Sequencing of mRNA also can be employed. For the most part, some or all of the coding sequence for the polypeptide having desaturase activity is from a natural source. In some situations, however, it is desirable to modify all or a portion of the codons, for example, to enhance expression, by employing host preferred codons. Host preferred codons can be determined from the codons of highest frequency in the proteins expressed in the largest amount in a particular host species of interest. Thus, the coding sequence for a polypeptide having desaturase activity can be synthesized in whole or in part. All or portions of the DNA also can be synthesized to remove any destabilizing sequences or regions of secondary structure which would be present in the transcribed mRNA. All or portions of the DNA also can be synthesized to alter the base composition to one more preferable in the desired host cell. Methods for synthesizing sequences and bringing sequences together are well established in the literature. In vitro mutagenesis and selection, site-directed mutagenesis, or other means can be employed to obtain mutations of naturally occurring desaturase genes to produce a polypeptide having desaturase activity in vivo with more desirable physical and kinetic parameters for function in the host cell, such as a longer half-life or a higher rate of production of a desired polyunsaturated fatty acid.

Mortieralla alpina Desaturase

Of particular interest is the Mortierella alpina Δ6-desaturase, which has

457 amino acids and a predicted molecular weight of 51.8 kD; the amino acid sequence is shown in Figure 3. The gene encoding the Mortierella alpina Δ6- desaturase can be expressed in transgenic microorganisms or animals to effect greater synthesis of GLA from linoleic acid or of stearidonic acid from ALA. Other DNAs which are substantially identical to the Mortierella alpina Δ6- desaturase DNA, or which encode polypeptides which are substantially identical to the Mortierella alpina Δ6-desaturase polypeptide, also can be used. By substantially identical is intended an amino acid sequence or nucleic acid sequence exhibiting in order of increasing preference at least 60%, 80%, 90% or 95% homology to the Mortierella alpina Δ6-desaturase amino acid sequence or nucleic acid sequence encoding the amino acid sequence. For polypeptides, the length of comparison sequences generally is at least 16 amino acids, preferably at least 20 amino acids, or most preferably 35 amino acids. For nucleic acids, the length of comparison sequences generally is at least 50 nucleotides, preferably at least 60 nucleotides, and more preferably at least 75 nucleotides, and most preferably, 110 nucleotides. Homology typically is measured using sequence analysis software, for example, the Sequence Analysis software package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wisconsin 53705, MEGAlign (DNAStar, Inc., 1228 S. Park St., Madison, Wisconsin 53715), and Mac Vector (Oxford Molecular Group, 2105 S. Bascom Avenue, Suite 200,

Campbell, California 95008). Such software matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine and leucine; aspartic acid, glutamic acid, asparagine, and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine. Substitutions may also be made on the basis of conserved hydrophobicity or hydrophilicity (Kyte and Doolittle, J. Mol. Biol. 157: 105-132, 1982), or on the basis of the ability to assume similar polypeptide secondary structure (Chou and Fasman, Adv. Enzymol. 47: 45-148, 1978).

Also of interest is the Mortierella alpina Δ12-desaturase, the nucleotide and amino acid sequence of which is shown in Figure 5. The gene encoding the Mortierella alpina Δ12-desaturase can be expressed in transgenic microorganisms or animals to effect greater synthesis of LA from oleic acid. Other DNAs which are substantially identical to the Mortierella alpina Δ12- desaturase DNA, or which encode polypeptides which are substantially identical to the Mortierella alpina Δ12-desaturase polypeptide, also can be used.

Other Desaturases

Encompassed by the present invention are related desaturases from the same or other organisms. Such related desaturases include variants of the disclosed Δ6- or Δ12-desaturase naturally occurring within the same or different species of Mortierella, as well as homologues of the disclosed Δ6- or Δ12- desaturase from other species. Also included are desaturases which, although not substantially identical to the Mortierella alpina Δ6- or Δ12-desaturase, desaturate a fatty acid molecule at carbon 6 or 12, respectively, from the carboxyl end of a fatty acid molecule, or at carbon 12 or 6 from the terminal methyl carbon in an 18 carbon fatty acid molecule. Related desaturases can be identified by their ability to function substantially the same as the disclosed desaturases; that is, are still able to effectively convert LA to GLA, ALA to SDA or oleic acid to LA. Related desaturases also can be identified by screening sequence databases for sequences homologous to the disclosed desaturases, by hybridization of a probe based on the disclosed desaturases to a library constructed from the source organism, or by RT-PCR using mRNA from the source organism and primers based on the disclosed desaturases. Such desaturases include those from humans, Dictyostelium discoideum and

Phaeodactylum tricornum.

The regions of a desaturase polypeptide important for desaturase activity can be determined through routine mutagenesis, expression of the resulting mutant polypeptides and determination of their activities. Mutants may include deletions, insertions and point mutations, or combinations thereof. A typical functional analysis begins with deletion mutagenesis to determine the N- and C- terminal limits of the protein necessary for function, and then internal deletions, insertions or point mutants are made to further determine regions necessary for function. Other techniques such as cassette mutagenesis or total synthesis also can be used. Deletion mutagenesis is accomplished, for example, by using exonucleases to sequentially remove the 5' or 3' coding regions. Kits are available for such techniques. After deletion, the coding region is completed by ligating oligonucleotides containing start or stop codons to the deleted coding region after 5' or 3' deletion, respectively. Alternatively, oligonucleotides encoding start or stop codons are inserted into the coding region by a variety of methods including site-directed mutagenesis, mutagenic PCR or by ligation onto DNA digested at existing restriction sites. Internal deletions can similarly be made through a variety of methods including the use of existing restriction sites in the DNA, by use of mutagenic primers via site directed mutagenesis or mutagenic PCR. Insertions are made through methods such as linker-scanning mutagenesis, site-directed mutagenesis or mutagenic PCR. Point mutations are made through techniques such as site-directed mutagenesis or mutagenic PCR.

Chemical mutagenesis also can be used for identifying regions of a desaturase polypeptide important for activity. A mutated construct is expressed, and the ability of the resulting altered protein to function as a desaturase is assayed. Such structure-function analysis can determine which regions may be deleted, which regions tolerate insertions, and which point mutations allow the mutant protein to function in substantially the same way as the native desaturase. All such mutant proteins and nucleotide sequences encoding them are within the scope of the present invention.

EXPRESSION OF DESATURASE GENES Once the DNA encoding a desaturase polypeptide has been obtained, it is placed in a vector capable of replication in a host cell, or is propagated in vitro by means of techniques such as PCR or long PCR. Replicating vectors can include plasmids, phage, viruses, cosmids and the like. Desirable vectors include those useful for mutagenesis of the gene of interest or for expression of the gene of interest in host cells. The technique of long PCR has made in vitro propagation of large constructs possible, so that modifications to the gene of interest, such as mutagenesis or addition of expression signals, and propagation of the resulting constructs can occur entirely in vitro without the use of a replicating vector or a host cell. For expression of a desaturase polypeptide, functional transcriptional and translational initiation and termination regions are operably linked to the DNA encoding the desaturase polypeptide. Expression of the polypeptide coding region can take place in vitro or in a host cell. Transcriptional and translational initiation and termination regions are derived from a variety of nonexclusive sources, including the DNA to be expressed, genes known or suspected to be capable of expression in the desired system, expression vectors, chemical synthesis, or from an endogenous locus in a host cell.

Expression In Vitro

In vitro expression can be accomplished, for example, by placing the coding region for the desaturase polypeptide in an expression vector designed for in vitro use and adding rabbit reticulocyte lysate and cofactors; labeled amino acids can be incorporated if desired. Such in vitro expression vectors may provide some or all of the expression signals necessary in the system used. These methods are well known in the art and the components of the system are commercially available. The reaction mixture can then be assayed directly for the polypeptide, for example by determining its activity, or the synthesized polypeptide can be purified and then assayed.

Expression In A Host Cell

Expression in a host cell can be accomplished in a transient or stable fashion. Transient expression can occur from introduced constructs which contain expression signals functional in the host cell, but which constructs do not replicate and rarely integrate in the host cell, or where the host cell is not proliferating. Transient expression also can be accomplished by inducing the activity of a regulatable promoter operably linked to the gene of interest, although such inducible systems frequently exhibit a low basal level of expression. Stable expression can be achieved by introduction of a construct that can integrate into the host genome or that autonomously replicates in the host cell. Stable expression of the gene of interest can be selected for through the use of a selectable marker located on or transfected with the expression construct, followed by selection for cells expressing the marker. When stable expression results from integration, integration of constructs can occur randomly within the host genome or can be targeted through the use of constructs containing regions of homology with the host genome sufficient to target recombination with the host locus. Where constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.

When increased expression of the desaturase polypeptide in the source organism is desired, several methods can be employed. Additional genes encoding the desaturase polypeptide can be introduced into the host organism.

Expression from the native desaturase locus also can be increased through homologous recombination, for example by inserting a stronger promoter into the host genome to cause increased expression, by removing destabilizing sequences from either the mRNA or the encoded protein by deleting that information from the host genome, or by adding stabilizing sequences to the mRNA (USPN 4,910,141).

When it is desirable to express more than one different gene, appropriate regulatory regions and expression methods, introduced genes can be propagated in the host cell through use of replicating vectors or by integration into the host genome. Where two or more genes are expressed from separate replicating vectors, it is desirable that each vector has a different means of replication. Each introduced construct, whether integrated or not, should have a different means of selection and should lack homology to the other constructs to maintain stable expression and prevent reassortment of elements among constructs. Judicious choices of regulatory regions, selection means and method of propagation of the introduced construct can be experimentally determined so that all introduced genes are expressed at the necessary levels to provide for synthesis of the desired products.

INTRODUCTION OF CONSTRUCTS INTO HOST CELLS

Constructs comprising the gene of interest may be introduced into a host cell by standard techniques. These techniques include transformation, protoplast fusion, lipofection, transfection, transduction, conjugation, infection, holistic impact, electroporation, microinjection, scraping, or any other method which introduces the gene of interest into the host cell. Methods of transformation which are used include lithium acetate transformation (Methods in Enzymology, Vol. 194, p. 186-187, 1991). For convenience, a host cell which has been manipulated by any method to take up a DNA sequence or construct will be referred to as "transformed" or "recombinant" herein.

The subject host will have at least have one copy of the expression construct and may have two or more, depending upon whether the gene is integrated into the genome, amplified, or is present on an extrachromosomal element having multiple copy numbers. Where the subject host is a yeast, four principal types of yeast plasmid vectors can be used: Yeast Integrating plasmids (Yips), Yeast Replicating plasmids (YRps), Yeast Centromere plasmids (YCps), and Yeast Episomal plasmids (YEps). Yips lack a yeast replication origin and must be propagated as integrated elements in the yeast genome. YRps have a chromosomally derived autonomously replicating sequence and are propagated as medium copy number (20 to 40), autonomously replicating, unstably segregating plasmids. YCps have both a replication origin and a centromere sequence and propagate as low copy number (10-20), autonomously replicating, stably segregating plasmids. YEps have an origin of replication from the yeast 2μm plasmid and are propagated as high copy number, autonomously replicating, irregularly segregating plasmids. The presence of the plasmids in yeast can be ensured by maintaining selection for a marker on the plasmid. Of particular interest are the yeast vectors pYES2 (a YEp plasmid available from Invitrogen, confers uracil prototrophy and a GAL1 galactose- inducible promoter for expression), pRS425-pGl (a YEp plasmid obtained from Dr. T. H. Chang, Ass. Professor of Molecular Genetics, Ohio State University, containing a constitutive GPD promoter and conferring leucine prototrophy), and pYX424 (a YEp plasmid having a constitutive TPl promoter and conferring leucine prototrophy; Alber, T. and Kawasaki, G. (1982). J. Mol. & Appl. Genetics 1: 419).

The transformed host cell can be identified by selection for a marker contained on the introduced construct. Alternatively, a separate marker construct may be introduced with the desired construct, as many transformation techniques introduce many DNA molecules into host cells. Typically, transformed hosts are selected for their ability to grow on selective media. Selective media may incorporate an antibiotic or lack a factor necessary for growth of the untransformed host, such as a nutrient or growth factor. An introduced marker gene therefor may confer antibiotic resistance, or encode an essential growth factor or enzyme, and permit growth on selective media when expressed in the transformed host. Selection of a transformed host can also occur when the expressed marker protein can be detected, either directly or indirectly. The marker protein may be expressed alone or as a fusion to another protein. The marker protein can be detected by its enzymatic activity; for example β galactosidase can convert the substrate X-gal to a colored product, and luciferase can convert luciferin to a light-emitting product. The marker protein can be detected by its light-producing or modifying characteristics; for example, the green fluorescent protein of Aequorea victoria fluoresces when illuminated with blue light. Antibodies can be used to detect the marker protein or a molecular tag on, for example, a protein of interest. Cells expressing the marker protein or tag can be selected, for example, visually, or by techniques such as FACS or panning using antibodies. For selection of yeast transformants, any marker that functions in yeast may be used. Desirably, resistance to kanamycin and the amino glycoside G418 are of interest, as well as ability to grow on media lacking uracil, leucine, lysine or tryptophan. Of particular interest is the Δ6- and Δ12-desaturase-mediated production of PUFAs in prokaryotic and eukaryotic host cells. Prokaryotic cells of interest include Eschericia, Bacillus, Lactobacillus, cyanobacteria and the like. Eukaryotic cells include mammalian cells such as those of lactating animals, avian cells such as of chickens, and other cells amenable to genetic manipulation including insect, fungal, and algae cells. The cells may be cultured or formed as part or all of a host organism including an animal. Viruses and bacteriophage also may be used with the cells in the production of PUFAs, particularly for gene transfer, cellular targeting and selection. In a preferred embodiment, the host is any microorganism or animal which produces and/or can assimilate exogenously supplied substrate(s) for a Δ6- and/or Δ12- desaturase, and preferably produces large amounts of one or more of the substrates. Examples of host animals include mice, rats, rabbits, chickens, quail, turkeys, bovines, sheep, pigs, goats, yaks, etc., which are amenable to genetic manipulation and cloning for rapid expansion of the transgene expressing population. For animals, the desaturase transgene(s) can be adapted for expression in target organelles, tissues and body fluids through modification of the gene regulatory regions. Of particular interest is the production of PUFAs in the breast milk of the host animal.

Expression in Insect Cells

Production of PUFAs in insect cells can be conducted using baculovirus expression vectors harboring one or more desaturase transgenes as detailed in the Example Section below. Examples of host systems include Spodoptera frugiperda (Sf9 and Sf21 cells) and cabbage lopper moth Trichoplusia ni (Hi Five cells).

Use of the baculovirus expression system in transgenic insect cells offers a number of advantages in PUFA production. Baculovirus expression systems are high level gene expression systems capable of post translational modifications similar to mammalian cells. The expression system allows for genetic manipulation with relative ease in comparison to mammalian cell transfections. By using site-specific transposition and eliminating the potential mix of parental and nonrecombinant baculoviruses, there is no need for multiple rounds of plaque purification. This greatly reduces the time it takes to identify and purify a recombinant virus. This system also offers the advantage of supporting coexpression of gene products encoded by different recombinant baculovirus vectors in a single infection.

Expression in Algae Cells

Methods for producing hybrid and transgenic strains of algae, such as marine algae, which contain and express a desaturase transgene also are provided. For example, transgenic marine algae may be prepared as described in USPN 5,426,040. As with the other expression systems described above, the timing, extent of expression and activity of the desaturase transgene can be regulated by fitting the polypeptide coding sequence with the appropriate transcriptional and translational regulatory regions selected for a particular use. Of particular interest are promoter regions which can be induced under preselected growth conditions. For example, introduction of temperature sensitive and/or metabolite responsive mutations into the desaturase transgene coding sequences, its regulatory regions, and/or the genome of cells into which the transgene is introduced can be used for this purpose. The transformed host cell is grown under appropriate conditions adapted for a desired end result. For host cells grown in culture, the conditions are typically optimized to produce the greatest or most economical yield of PUFAs, which relates to the selected desaturase activity. Media conditions which may be optimized include: carbon source, nitrogen source, addition of substrate, final concentration of added substrate, form of substrate added, aerobic or anaerobic growth, growth temperature, inducing agent, induction temperature, growth phase at induction, growth phase at harvest, pH, density, and maintenance of selection. Microorganisms of interest, such as yeast and algae are preferably grown in selected medium. For yeast, complex media such as peptone broth (YPD) or a defined media such as a minimal media (contains amino acids, yeast nitrogen base, and ammonium sulfate, and lacks a component for selection, for example uracil) are preferred. Desirably, substrates to be added are first dissolved in ethanol. Where necessary, expression of the polypeptide of interest may be induced, for example by including or adding galactose to induce expression from a GAL promoter.

Expression In Animals and Animal Cells

Expression in cells of a host animal can likewise be accomplished in a transient or stable manner. Transient expression can be accomplished via known methods, for example infection or lipofection, and can be repeated in order to maintain desired expression levels of the introduced construct (see Ebert, PCT publication WO 94/05782). Stable expression can be accomplished via integration of a construct into the host genome, resulting in a transgenic animal. The construct can be introduced, for example, by microinjection of the construct into the pronuclei of a fertilized egg, or by transfection, retroviral infection or other techniques whereby the construct is introduced into a cell line which may form or be incorporated into an adult animal (U.S. Patent No. 4,873,191; U.S.

Patent No. 5,530,177; U.S. Patent No. 5,565,362; U.S. Patent No. 5,366,894; Willmut et al (1997) Nature 385:810). The recombinant eggs or embryos are transferred to a surrogate mother (U.S. Patent No. 4,873,191; U.S. Patent No. 5,530,177; U.S. Patent No. 5,565,362; U.S. Patent No. 5,366,894; Wilmut etal (supra)).

After birth, transgenic animals are identified, for example, by the presence of an introduced marker gene, such as for coat color, or by PCR or Southern blotting from a blood, milk or tissue sample to detect the introduced construct, or by an immunological or enzymological assay to detect the expressed protein or the products produced therefrom (U.S. Patent No.

4,873,191; U.S. Patent No. 5,530,177; U.S. Patent No. 5,565,362; U.S. Patent No. 5,366,894; Wilmut et al (supra)). The resulting transgenic animals may be entirely transgenic or may be mosaics, having the transgenes in only a subset of their cells. The advent of mammalian cloning, accomplished by fusing a nucleated cell with an enucleated egg, followed by transfer into a surrogate mother, presents the possibility of rapid, large-scale production upon obtaining a "founder" animal or cell comprising the introduced construct; prior to this, it was necessary for the transgene to be present in the germ line of the animal for propagation (Wilmut et al (supra)). Expression in a host animal presents certain efficiencies, particularly where the host is a domesticated animal. For production of PUFAs in a fluid readily obtainable from the host animal, such as milk, the desaturase transgene can be expressed in mammary cells from a female host, and the PUFA content of the host cells altered. The desaturase transgene can be adapted for expression so that it is retained in the mammary cells, or secreted into milk, to form the

PUFA reaction products localized to the milk (PCT publication WO 95/24488). Expression can be targeted for expression in mammary tissue using specific regulatory sequences, such as those of bovine α-lactalbumin, α-casein, β- casein, γ-casein, κ-casein, β-lactoglobulin, or whey acidic protein, and may optionally include one or more introns and/or secretory signal sequences (U.S. Patent No. 5,530,177; Rosen, U.S. Patent No. 5,565,362; Clark et al, U.S. Patent No. 5,366,894; Garner et al, PCT publication WO 95/23868).

Expression of desaturase transgenes, or antisense desaturase transcripts, adapted in this manner can be used to alter the levels of specific PUFAs, or derivatives thereof, found in the animals milk. Additionally, the desaturase transgene(s) can be expressed either by itself or with other transgenes, in order to produce animal milk containing higher proportions of desired PUFAs or PUFA ratios and concentrations that resemble human breast milk (Prieto et al, PCT publication WO 95/24494).

PURIFICATION OF Δ6, Δ9, Δ12 and Δ15 DESATURASES

Recombinant Δ6, Δ9, Δ12 or Δ15 desaturases may be purified from cell lysates and extracts, or from conditoned culture medium, by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography. Insect cell produced Δ6, Δ9, Δ12 or Δ15 desaturase is a particularly good source of the purified enzyme. The purified Δ6, Δ9, Δ 12 or Δ 15 desaturase may be used for the production of monoclnal and polyclonal antibodies.

In addition, recombinant Δ6, Δ9, Δ12 or Δ15 desaturases can be separated from other cellular proteins by use of an immuno-affinity column made with monoclonal or polyclonal antibodies specific for full length Δ6, Δ9, Δ 12 or Δ 15 desaturase or polypeptide fragments of Δ6, Δ9, Δ 12 or Δ 15 desaturase.

Δ6, Δ9, Δ12 and Δ15 DESATURASE ANTIBODIES

Monospecific antibodies to Δ6, Δ9, Δ12 or Δ15 desaturases are purified from mammalian antisera containing antibodies reactive against Δ6, Δ9, Δ12 or Δ15 desaturase or are prepared as monoclonal antibodies reactive with Δ6, Δ9, Δ12, Δ15 desaturase using procedures well known in the art such as the technique of Kohler and milstein, Nature 256: 495-497 (1975). Monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for Δ6, Δ9, Δ12 or Δ15 desaturase. Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with the Δ6, Δ9, Δ 12 or Δ 15 desaturase, as described above. Δ6, Δ9, Δ12 or Δ15 desaturase specific antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats, horses and the like, with an appropriate concentration of Δ6, Δ9, Δ12 or Δ15 desaturase either with or without an immune adjuvant.

Polyclonal Antibodies

Preimmune serum is collected prior to the first immunization. Each animal receives between about 0.1 μg and about 1000 μg of Δ6, Δ9, Δ12 or Δ15 desaturase associated with an acceptable immune adjuvant. Such acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing Corynebacterium parvum and tRNA. The initial immunization consists of the Δ6, Δ9, Δ 12 or Δ 15 desaturase protein in, preferably, Freund's complete adjuvant at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization. Those animals receiving booster injections are generally given an equal amount of Δ6, Δ9, Δ12 or Δ15 desaturase in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about -20° C.

Monoclonal Antibodies Monoclonal antibodies (mAb) reactive with Δ6, Δ9, Δ12 or Δ15 desaturase are prepared by immunizing inbred mice, preferably Balb/c, with PTP-OB. The mice are immunized by the IP or SC route with about 1 μg to about 100 μg, preferably about 10 μg of Δ6, Δ9, Δ12 or Δ15 desaturase in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed above. Freund's complete adjuvant is preferred. The mice receive an initial immunization on day 0 and are rested for about 3 to about 30 weeks. Immunized mice are given one or more booster immunizations of about 1 to about 100 μg of Δ6, Δ9, Δ12 or Δ15 desaturase in a buffer solution such as phosphate buffered saline by the intravenous (IV) route. Lymphocytes, from antibody positive mice, preferably splenic lymphocytes, are obtained by removing spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NS 1/Ag 4-1 ; MPC-11; S-194 and Sp 2/0 being preferred.

The antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected from growth positive wells on or about days 14, 18 and 21 and are screened for Δ6, Δ9, Δ12 or Δ15 desaturase antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using Δ6, Δ9, Δ12 or Δ15 desaturase as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, Soft Agar Techniques in Tissue Culture Methods and Applications, Kruse and Paterson, Eds., Academic Press, 1973.

Monoclonal antibodies are produced in vito by injection of pristane primed Balb/c mice, approximately 0.5 ml per mouse, with about 2 x 10⁶ to about 6 x 10^{6 hybπdoma} cells about 4 days after priming. Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.

In vitro production of anti-Δ6, Δ9, Δ12 or Δ15 desaturase mAb is carried out by growing the dydridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art.

Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of Δ6, Δ9, Δ12 or Δ15 desaturases in body fluids or tissue and cell extracts.

It is readily apparent to those skilled in the art that the above described methods of reproducing Monospecific antibodies may be utilized to produce antibodies specific for Δ6, Δ9, Δ12 or Δ15 desaturase polypeptide fragments, or full-length Δ6, Δ9, Δ12 or Δ15 desaturase polypeptide.

Δ6, Δ9, Δ12 or Δ15 desaturase antibody affinity columns are made by adding the antibodies to Affigel-10 (Biorad), a gel support which is pre- activated with N-hydroxysuccinimide esters such that the antibodies form covalent linkages with the agarose gel bead support. The antibodies are then coupled to the gel via amide bonds with the spacer arm. The remaining activated esters are then quenched with 1M ethanolamine (HCl (pH 8). The column is washed with water followed by 0.23M glycine HCl (pH 2.6) to remove any non-conjugated antibody or extraneous protein. The column is then equilibrated in phosphate buffered saline (pH 7.3) and the cell culture supernatants or cell extracts containing Δ6, Δ9, Δ12 or Δ15 desaturase or Δ6, Δ9, Δ12 or Δ15 desaturase fragments are slowly passed through the column. The column is then washed with phosphate buffered saline until the optical density (A280) falls to background, then the protein is eluted with 0.23M glycine-HCI (pH 2.6). The purified Δ6, Δ9, Δ12 or Δ15 desaturase protein is then dialyzed against phosphate buffered saline. PURIFICATION OF FATTY ACIDS

The desaturated fatty acids may be found in the host microorganism or animal as free fatty acids or in conjugated forms such as acylglycerols, phospholipids, sulfolipids or glycolipids, and may be extracted from the host cell through a variety of means well-known in the art. Such means may include extraction with organic solvents, sonication, supercritical fluid extraction using for example carbon dioxide, and physical means such as presses, or combinations thereof. Of particular interest is extraction with hexane or methanol and chloroform. Where desirable, the aqueous layer can be acidified to protonate negatively charged moieties and thereby increase partitioning of desired products into the organic layer. After extraction, the organic solvents can be removed by evaporation under a stream of nitrogen. When isolated in conjugated forms, the products may be enzymatically or chemically cleaved to release the free fatty acid or a less complex conjugate of interest, and can then be subject to further manipulations to produce a desired end product. Desirably, conjugated forms of fatty acids are cleaved with potassium hydroxide.

If further purification is necessary, standard methods can be employed.

Such methods may include extraction, treatment with urea, fractional crystallization, HPLC, fractional distillation, silica gel chromatography, high speed centrifugation or distillation, or combinations of these techniques.

Protection of reactive groups, such as the acid or alkenyl groups, may be done at any step through known techniques, for example alkylation or iodination.

Methods used include methylation of the fatty acids to produce methyl esters.

Similarly, protecting groups may be removed at any step. Desirably, purification of fractions containing GLA, SDA, ARA, DHA and EPA may be accomplished by treatment with urea and/or fractional distillation.

USES OF FATTY ACIDS

The fatty acids of the subject invention finds many applications. Probes based on the DNAs of the present invention may find use in methods for isolating related molecules or in methods to detect organisms expressing desaturases. When used as probes, the DNAs or oligonucleotides must be detectable. This is usually accomplished by attaching a label either at an internal site, for example via incorporation of a modified residue, or at the 5' or 3' terminus. Such labels can be directly detectable, can bind to a secondary molecule that is detectably labeled, or can bind to an unlabelled secondary molecule and a detectably labeled tertiary molecule; this process can be extended as long as is practical to achieve a satisfactorily detectable signal without unacceptable levels of background signal. Secondary, tertiary, or bridging systems can include use of antibodies directed against any other molecule, including labels or other antibodies, or can involve any molecules which bind to each other, for example a biotin-streptavidin/avidin system.

Detectable labels typically include radioactive isotopes, molecules which chemically or enzymatically produce or alter light, enzymes which produce detectable reaction products, magnetic molecules, fluorescent molecules or molecules whose fluorescence or light-emitting characteristics change upon binding. Examples of labeling methods can be found in USPN 5,011,770.

Alternatively, the binding of target molecules can be directly detected by measuring the change in heat of solution on binding of probe to target via isothermal titration calorimetry, or by coating the probe or target on a surface and detecting the change in scattering of light from the surface produced by binding of target or probe, respectively, as may be done with the BIAcore system.

PUFAs produced by recombinant means find applications in a wide variety of areas. Supplementation of animals or humans with PUFAs in various forms can result in increased levels not only of the added PUFAs but of their metabolic progeny as well.

NUTRITIONAL COMPOSITIONS

The present invention also includes nutritional compositions. Such compositions, for purposes of the present invention, include any food or preparation for human consumption including for enteral or parenteral consumption, which when taken into the body (a) serve to nourish or build up tissues or supply energy and/or (b) maintain, restore or support adequate nutritional status or metabolic function. The nutritional composition of the present invention comprises at least one oil or acid produced in accordance with the present invention and may either be in a solid or liquid form. Additionally, the composition may include edible macronutrients, vitamins and minerals in amounts desired for a particular use. The amount of such ingredients will vary depending on whether the composition is intended for use with normal, healthy infants, children or adults having specialized needs such as those which accompany certain metabolic conditions (e.g., metabolic disorders).

Examples of macronutrients which may be added to the composition include but are not limited to edible fats, carbohydrates and proteins. Examples of such edible fats include but are not limited to coconut oil, soy oil, and mono- and diglycerides. Examples of such carbohydrates include but are not limited to glucose, edible lactose and hydrolyzed search. Additionally, examples of proteins which may be utilized in the nutritional composition of the invention include but are not limited to soy proteins, electrodialysed whey, electrodialysed skim milk, milk whey, or the hydrolysates of these proteins.

With respect to vitamins and minerals, the following may be added to the nutritional compositions of the present invention: calcium, phosphorus, potassium, sodium, chloride, magnesium, manganese, iron, copper, zinc, selenium, iodine, and Vitamins A, E, D, C, and the B complex. Other such vitamins and minerals may also be added.

The components utilized in the nutritional compositions of the present invention will of semi-purified or purified origin. By semi-purified or purified is meant a material which has been prepared by purification of a natural material or by synthesis.

Examples of nutritional compositions of the present invention include but are not limited to infant formulas, dietary supplements, and rehydration compositions. Nutritional compositions of particular interest include but are not limited to those utilized for enteral and parenteral supplementation for infants, specialist infant formulae, supplements for the elderly, and supplements for those with gastrointestinal difficulties and/or malabsorption. Nutritional Compositions

A typical nutritional composition of the present invention will contain edible macronutrients, vitamins and minerals in amounts desired for a particular use. The amounts of such ingredients will vary depending on whether the formulation is intended for use with normal, healthy individuals temporarily exposed to stress, or to subjects having specialized needs due to certain chronic or acute disease states (e.g., metabolic disorders). It will be understood by persons skilled in the art that the components utilized in a nutritional formulation of the present invention are of semi-purified or purified origin. By semi-purified or purified is meant a material that has been prepared by purification of a natural material or by synthesis. These techniques are well known in the art (See, e.g., Code of Federal Regulations for Food Ingredients and Food Processing; Recommended Dietary Allowances, 10^th Ed., National Academy Press, Washington, D.C., 1989). In a preferred embodiment, a nutritional formulation of the present invention is an enteral nutritional product, more preferably an adult or child enteral nutritional product. Accordingly in a further aspect of the invention, a nutritional formulation is provided that is suitable for feeding adults or children, who are experiencing stress. The formula comprises, in addition to the PUFAs of the invention; macronutrients, vitamins and minerals in amounts designed to provide the daily nutritional requirements of adults.

The macronutritional components include edible fats, carbohydrates and proteins. Exemplary edible fats are coconut oil, soy oil, and mono- and diglycerides and the PUFA oils of this invention. Exemplary carbohydrates are glucose, edible lactose and hydrolyzed cornstarch. A typical protein source would be soy protein, electrodialysed whey or electrodialysed skim milk or milk whey, or the hydrolysates of these proteins, although other protein sources are also available and may be used. These macronutrients would be added in the form of commonly accepted nutritional compounds in amount equivalent to those present in human milk or an energy basis, i.e., on a per calorie basis. Methods for formulating liquid and enteral nutritional formulas are well known in the art and are described in detail in the examples.

The enteral formula can be sterilized and subsequently utilized on a ready-to-feed (RTF) basis or stored in a concentrated liquid or a powder. The powder can be prepared by spray drying the enteral formula prepared as indicated above, and the formula can be reconstituted by rehydrating the concentrate. Adult and infant nutritional formulas are well known in the art and commercially available (e.g., Similac®, Ensure®, Jevity® and Alimentum® from Ross Products Division, Abbott Laboratories). An oil or acid of the present invention can be added to any of these formulas in the amounts described below.

The energy density of the nutritional composition when in liquid form, can typically range from about 0.6 to 3.0 Kcal per ml. When in solid or powdered form, the nutritional supplement can contain from about 1.2 to more than 9 Kcals per gm, preferably 3 to 7 Kcals per gm. In general, the osmolality of a liquid product should be less than 700 mOsm and more preferably less than 660 mOsm.

The nutritional formula would typically include vitamins and minerals, in addition to the PUFAs of the invention, in order to help the individual ingest the minimum daily requirements for these substances. In addition to the PUFAs listed above, it may also be desirable to supplement the nutritional composition with zinc, copper, and folic acid in addition to antioxidants. It is believed that these substances will also provide a boost to the stressed immune system and thus will provide further benefits to the individual. The presence of zinc, copper or folic acid is optional and is not required in order to gain the beneficial effects on immune suppression. Likewise a pharmaceutical composition can be supplemented with these same substances as well.

In a more preferred embodiment, the nutritional contains, in addition to the antioxidant system and the PUFA component, a source of carbohydrate wherein at least 5 weight % of said carbohydrate is an indigestible oligosaccharide. In yet a more preferred embodiment, the nutritional composition additionally contains protein, taurine and carnitine.

The PUFAs, or derivatives thereof, made by the disclosed method can be used as dietary substitutes, or supplements, particularly infant formulas, for patients undergoing intravenous feeding or for preventing or treating malnutrition. Typically, human breast milk has a fatty acid profile comprising from about 0.15 % to about 0.36 % as DHA, from about 0.03 % to about 0.13 % as EPA, from about 0.30 % to about 0.88 % as ARA, from about 0.22 % to about 0.67 % as DGLA, and from about 0.27 % to about 1.04 % as GLA. Additionally, the predominant triglyceride in human milk has been reported to be l,3-di-oleoyl-2-palmitoyl, with 2-palmitoyl glycerides reported as better absorbed than 2-oleoyl or 2-lineoyl glycerides (USPN 4,876,107). Thus, fatty acids such as ARA, DGLA, GLA and/or EPA produced by the invention can be used to alter the composition of infant formulas to better replicate the PUFA composition of human breast milk. In particular, an oil composition for use in a pharmacologic or food supplement, particularly a breast milk substitute or supplement, will preferably comprise one or more of ARA, DGLA and GLA. More preferably the oil will comprise from about 0.3 to 30% ARA, from about 0.2 to 30% DGLA, and from about 0.2 to about 30% GLA. In addition to the concentration, the ratios of ARA, DGLA and GLA can be adapted for a particular given end use. When formulated as a breast milk supplement or substitute, an oil composition which contains two or more of ARA, DGLA and GLA will be provided in a ratio of about 1:19:30 to about 6: 1 :0.2, respectively. For example, the breast milk of animals can vary in ratios of ARA:DGLA:DGL ranging from 1 : 19:30 to 6: 1 :0.2, which includes intermediate ratios which are preferably about 1:1:1, 1:2:1, 1:1:4. When produced together in a host cell, adjusting the rate and percent of conversion of a precursor substrate such as GLA and DGLA to ARA can be used to precisely control the PUFA ratios. For example, a 5% to 10% conversion rate of DGLA to ARA can be used to produce an ARA to DGLA ratio of about 1:19, whereas a conversion rate of about 75% to 80% can be used to produce an ARA to DGLA ratio of about 6: 1. Therefore, whether in a cell culture system or in a host animal, regulating the timing, extent and specificity of desaturase expression as described can be used to modulate the PUFA levels and ratios. Depending on the expression system used, e.g., cell culture or an animal expressing oil(s) in its milk, the oils also can be isolated and recombined in the desired concentrations and ratios. Amounts of oils providing these ratios of

PUFA can be determined following standard protocols. PUFAs, or host cells containing them, also can be used as animal food supplements to alter an animal's tissue or milk fatty acid composition to one more desirable for human or animal consumption. For dietary supplementation, the purified PUFAs, or derivatives thereof, may be incorporated into cooking oils, fats or margarines formulated so that in normal use the recipient would receive the desired amount. The PUFAs may also be incorporated into infant formulas, nutritional supplements or other food products, and may find use as anti-inflammatory or cholesterol lowering agents.

Pharmaceutical Compositions

The present invention also encompasses a pharmaceutical composition comprising one or more of the acids and/or resulting oils produced in accordance with the methods described herein. More specifically, such a pharmaceutical composition may comprise one or more of the acids and/or oils as well as a standard, well-known, non-toxic pharmaceutically acceptable carrier, adjuvant or vehicle such as, for example, phosphate buffered saline, water, ethanol, polyols, vegetable oils, a wetting agent or an emulsion such as a water/oil emulsion. The composition may be in either a liquid or solid form. For example, the composition may be in the form of a tablet, capsule, ingestible liquid or powder, injecaible, or topical ointment or cream.

Possible routes of administration include, for example, oral, rectal and parenteral. The route of administration will, of course, depend upon the desired effect. For example, if the composition is being utilized to treat rough, dry, or aging skin, to treat injured or burned skin, or to treat skin or hair affected by a disease or condition, it may perhaps be applied topically. The dosage of the composition to be administered to the patient may be determined by one of ordinary skill in the art and depends upon various factors such as weight of the patient, age of the patient, immune status of the patient, etc. With respect to form, the composition may be, for example, a solution, a dispersion, a suspension, an emulsion or a sterile powder which is then reconstituted.

Cosmetic Compositions

Additionally, the composition of the present invention may be utilized for cosmetic purposes. It may be added to pre-existing cosmetic compositions such that a mixture is formed or may be used as a sole composition.

The topical compositions into which PUFAs or oils of this invention are formulated comprise a cosmetic or dermatological composition and can be provided in all conventional pharmaceutical dosage forms for topical application and the physiologically acceptable vehicle, diluent or carrier therefore can be any standard vehicle or medium for a cosmetic or dermatological composition The subject compositions can be formulated as an aqueous solution, or an oily suspension, or a dispersion of the lotion or serum type, or as an emulsion having a liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase into an aqueous phase (O/W) or vice- verse (W/O), or as a suspension or emulsion having a soft consistency of the aqueous gel or cream type, or as microcapsules or microparticles, or as vesticular dispersions of ionic and/or non-ionic type. These compositions are formulated according to the usual techniques. The amounts of the different constituents of the compositions are those conventionally employed in the fields under consideration.

The subject compositions constitute, in particular, cleansing, protection, treatment or care of creams for the face, for the hands, for the major anatomical folds or for the body (for example day creams, night creams, makeup removal creams, foundation creams or anti-sun or sunscreen creams), fluid foundations, makeup removal milks, protection or care body milds, anti-sun or sunscreen milks, or lotions, gels or foams for caring for the skin, such as cleansing lotions, anti-sun lotions, artificial tanning lotions, an the like.

When the composition is an emulsion, the proportion of the fatty phase can range from 5% to 80% by weight and preferably from 5% to 50% by weight with respect to the total weight of the composition. The oils, waxes, emulsifiers, and coemulsifiers formulated into the composition in the emulsion form are those conventional in the cosmetics field. The emulsifier and the coemulsifier are advantageously present in such compositions in a proportion ranging from 0.3% to 30% by weight and preferably from 0.5% to 20% by weight with respect to the total weight of the composition. The emulsion can, in addition, contain lipid vesicles.

The subject cosmetic or dermatological compositions can also contain adjuvants and additives usual in the cosmetics or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, fragrances, fillers, screening agents, odor absorbers and colorants. The amounts of these different adjuvants and additives are those conventional in these fields and, for example, range from 0.01% to 10% of the total weight of the composition. These adjuvants and additives, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and/or into lipid spherules.

Exemplary oils and waxes include mineral oils (liquid petrolatum), vegetable oils (liquid fraction of karite butter, sunflower oil), animal oils (perhydrosqualene), synthetic oils (Purcellin oil), silicone oils or waxes (cyclomethicone) and fluorinated oils (perfluoropolyethers), beeswax or carnauba or paraffin wax. Fatty alcohols and fatty acids (stearic acid) can be added to these oils.

Exemplary emulsifiers include, for example, glycerol stearate, polysorbate 60 and the PEG-6/PEG-32/glycol stearate mixture marketed under the trademark Tefose ^® 63 by Gattefosse. Exemplary hydrophilic gelling agents according to the invention include the carboxyvinyl polymers (carbomer), acrylic copolymers, such as acrylate/alkyl acrylate copolymers, polyacrylamides, polysaccharides, such as hydroxypropylcellulose, natural gums and clays, and exemplary lipophilic gelling agents include the modified clays, such as bentones, or metal salts of fatty acids, such as aluminum stearates. Insofar as they do not interfere or interact with the activity of the melatonin, the compositions of the present invention can contain other active ingredients suitable, in particular, for the prevention and/or for the treatment of skin conditions/afflictions.

The compositions according to the invention are particularly well suited for preventing or treating oxidative stress of the skin and/or of its adnexa, in particular related to UV irradiation, to aging, to inflammation, to alopecia, and the like.

Administration of the Pharmaceutical Compositions

Pharmaceutical compositions may be utilized to administer the PUFA component to an individual. Suitable pharmaceutical compositions may comprise physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile solutions or dispersions for ingestion. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth or mixtures of these substances, and the like.

Solid dosage forms such as tablets and capsules can be prepared using techniques well known in the art. For example, PUFAs of the invention can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders such as acacia, cornstarch or gelatin, disintegrating agents such as potato starch or alginic acid and a lubricant such as stearic acid or magnesium stearate. Capsules can be prepared by incorporating these excipients into a gelatin capsule along with the antioxidants and the PUFA component. The amount of the antioxidants and PUFA component that should be incorporated into the pharmaceutical formulation should fit within the guidelines discussed above.

As used in this application, the term "treat" refers to either preventing, or reducing the incidence of, the undesired occurrence. For example, to treat immune suppression refers to either preventing the occurrence of this suppression or reducing the amount of such suppression. The terms "patient" and "individual" are being used interchangeably and both refer to an animal. The term "animal" as used in this application refers to any warm-blooded mammal including, but not limited to, dogs, humans, monkeys, and apes. As used in the application the term "about" refers to an amount varying from the stated range or number by a reasonable amount depending upon the context of use. Any numerical number or range specified in the specification should be considered to be modified by the term about.

"Dose" and "serving" are used interchangeably and refer to the amount of the nutritional or pharmaceutical composition ingested by the patient in a single setting and designed to deliver effective amounts of the antioxidants and the structured triglyceride. As will be readily apparent to those skilled in the art, a single dose or serving of the liquid nutritional powder should supply the amount of antioxidants and PUFAs discussed above. The amount of the dose or serving should be a volume that a typical adult can consume in one sitting. This amount can vary widely depending upon the age, weight, sex or medical condition of the patient. However as a general guideline, a single serving or dose of a liquid nutritional produce should be considered as encompassing a volume from 100 to 600 ml, more preferably from 125 to 500 ml and most preferably from 125 to 300 ml.

Food Products The PUFAs of the present invention may also be added to food even when supplementation of the diet is not required. For example, the composition may be added to food of any type including but not limited to margarines, modified butters, cheeses, milk, yogurt, chocolate, candy, snacks, salad oils, cooking oils, cooking fats, meats, fish and beverages. Pharmaceutical Applications

For pharmaceutical use (human or veterinary), the compositions are generally administered orally but can be administered by any route by which they may be successfully absorbed, e.g., parenterally (i.e. subcutaneously, intramuscularly or intravenously), rectally or vaginally or topically, for example, as a skin ointment or lotion. The PUFAs of the present invention may be administered alone or in combination with a pharmaceutically acceptable carrier or excipient. Where available, gelatin capsules are the preferred form of oral administration. Dietary supplementation as set forth above also can provide an oral route of administration. The unsaturated acids of the present invention may be administered in conjugated forms, or as salts, esters, amides or prodrugs of the fatty acids. Any pharmaceutically acceptable salt is encompassed by the present invention; especially preferred are the sodium, potassium or lithium salts. Also encompassed are the N-alkylpolyhydroxamine salts, such as N-methyl glucamine, found in PCT publication WO 96/33155. The preferred esters are the ethyl esters. As solid salts, the PUFAs also can be administered in tablet form. For intravenous administration, the PUFAs or derivatives thereof may be incorporated into commercial formulations such as Intralipids. The typical normal adult plasma fatty acid profile comprises 6.64 to 9.46% of ARA, 1.45 to 3.11% of DGLA, and 0.02 to 0.08% of GLA. These PUFAs or their metabolic precursors can be administered, either alone or in mixtures with other PUFAs, to achieve a normal fatty acid profile in a patient. Where desired, the individual components of formulations may be individually provided in kit form, for single or multiple use. A typical dosage of a particular fatty acid is from 0.1 mg to 20 g, or even 100 g daily, and is preferably from 10 mg to 1, 2, 5 or 10 g daily as required, or molar equivalent amounts of derivative forms thereof. Parenteral nutrition compositions comprising from about 2 to about 30 weight percent fatty acids calculated as triglycerides are encompassed by the present invention; preferred is a composition having from about 1 to about 25 weight percent of the total PUFA composition as GLA (USPN 5,196,198). Other vitamins, and particularly fat-soluble vitamins such as vitamin A, D, E and L-carnitine can optionally be included. Where desired, a preservative such as α tocopherol may be added, typically at about 0.1 % by weight.

Suitable pharmaceutical compositions may comprise physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylleneglyol, polyethylenegycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ehyl oleate. Proper fluidity can be maintained, for example, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.

Suspensions in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances and the like. An especially preferred pharmaceutical composition contains diacetyltartaric acid esters of mono- and diglycerides dissolved in an aqueous medium or solvent. Diacetyltartaric acid esters of mono- and diglycerides have an HLB value of about 9-12 and are significantly more hydrophilic than existing antimicrobial lipids that have HLB values of 2-4. Those existing hydrophobic lipids cannot be formulated into aqueous compositions. As disclosed herein, those lipids can now be solubilized into aqueous media in combination with diacetyltartaric acid esters of mono-and diglycerides. In accordance with this embodiment, diacetyltartaric acid esters of mono- and diglycerides (e.g., DATEM-C12:0) is melted with other active antimicrobial lipids (e.g., 18:2 and

12:0 monoglycerides) and mixed to obtain a homogeneous mixture. Homogeneity allows for increased antimicrobial activity. The mixture can be completely dispersed in water. This is not possible without the addition of diacetyltartaric acid esters of mono- and diglycerides and premixing with other monoglycerides prior to introduction into water. The aqueous composition can then be admixed under sterile conditions with physiologically acceptable diluents, preservatives, buffers or propellants as may be required to form a spray or inhalant.

Treatments of Diseases and Disorders The present invention also encompasses the treatment of numerous disorders with fatty acids. Supplementation with PUFAs of the present invention can be used to treat restenosis after angioplasty. Symptoms of inflammation, rheumatoid arthritis, and asthma and psoriasis can be treated with the PUFAs of the present invention. Evidence indicates that PUFAs may be involved in calcium metabolism, suggesting that PUFAs of the present invention may be used in the treatment or prevention of osteoporosis and of kidney or urinary tract stones.

The PUFAs of the present invention can be used in the treatment of cancer. Malignant cells have been shown to have altered fatty acid compositions; addition of fatty acids has been shown to slow their growth and cause cell death, and to increase their susceptibility to chemotherapeutic agents. GLA has been shown to cause reexpression on cancer cells of the E-cadherin cellular adhesion molecules, loss of which is associated with aggressive metastasis. Clinical testing of intravenous administration of the water soluble lithium salt of GLA to pancreatic cancer patients produced statistically significant increases in their survival. PUFA supplementation may also be useful for treating cachexia associated with cancer.

The PUFAs of the present invention can also be used to treat diabetes (USPN 4,826,877; Horrobin et al, Am. J. Clin. Nutr. Vol. 57 (Suppl.), 732S- 737S). Altered fatty acid metabolism and composition has been demonstrated in diabetic animals. These alterations have been suggested to be involved in some of the long-term complications resulting from diabetes, including retinopathy, neuropathy, nephropathy and reproductive system damage. Primrose oil, which contains GLA, has been shown to prevent and reverse diabetic nerve damage.

The PUFAs of the present invention can be used to treat eczema, reduce blood pressure and improve math scores. Essential fatty acid deficiency has been suggested as being involved in eczema, and studies have shown beneficial effects on eczema from treatment with GLA. GLA has also been shown to reduce increases in blood pressure associated with stress, and to improve performance on arithmetic tests. GLA and DGLA have been shown to inhibit platelet aggregation, cause vasodilation, lower cholesterol levels and inhibit proliferation of vessel wall smooth muscle and fibrous tissue (Brenner et al, Adv. Exp. Med. Biol. Vol. 83, p. 85-101, 1976). Administration of GLA or DGLA, alone or in combination with EPA, has been shown to reduce or prevent gastro-intestinal bleeding and other side effects caused by non-steroidal anti- inflammatory drugs (USPN 4,666,701). GLA and DGLA have also been shown to prevent or treat endometriosis and premenstrual syndrome (USPN 4,758,592) and to treat myalgic encephalomyelitis and chronic fatigue after viral infections (USPN 5,116,871).

Further uses of the PUFAs of this invention include use in treatment of ADDS, multiple sclerosis, acute respiratory syndrome, hypertension and inflammatory skin disorders. The PUFAs of the inventions also can be used for formulas for general health as well as for geriatric treatments. Veterinary Applications

It should be noted that the above-described pharmaceutical and nutritional compositions may be utilized in connection with animals, as well as humans, as animals experience many of the same needs and conditions as human. For example, the oil or acids of the present invention may be utilized in animal feed supplements.

The following examples are presented by way of illustration, not of limitation.

Examples

Example 1 Construction of a cDNA Library from Mortierella alpina

Example 2 Isolation of a Δ6-desaturase Nucleotide Sequence from Mortierella alpina

Example 3 Identification of Δ6-desaturases Homologous to the Mortierella alpina Δ6-desaturase

Example 4 Isolation of a Δ12-desaturase Nucleotide Sequence from Mortierella Alpina

Example 5 Expression of M. alpina Desaturase Clones in Baker's Yeast

Example 6 Initial Optimization of Culture Conditions

Example 7 Distribution of PUFAs in Yeast Lipid Fractions

Example 8 Further Culture Optimization and Coexpression of Δ6 and Δ12-desaturases

Example 9 Expression of M. alpina of Δ6 and Δ12-desaturases genes in insect cells

Example 10 Identification of Homologues to M. alpina Δ5 and Δ6 desaturases Example 11 Identification of M. alpina Δ5 and Δ6 homologues in other PUFA-producing organisms

Example 12 Identification of M. alpina Δ5 and Δ6 homologues in other PUFA-producing organisms Example 13 Human Desaturase Gene Sequences

Example 14 Production of Oil in Microorganisms

Example 15 Further Processing of Oil Produced by Microorganisms

Example 16 Further Purification of Oil Produced by Microorganisms

Example 17 Manufacture of Transgenic Oil Nutritional Products Example 18 Nutritional Compositions

Example 1

Construction of a cDNA Library from Mortierella alpina

Total RNA was isolated from a 3 day old PUFA-producing culture of Mortierella alpina using the protocol of Hoge et al. (1982) Experimental

Mycology 6:225-232. The RNA was used to prepare double-stranded cDNA using BRL's lambda-ZipLox system following the manufactures instructions. Several size fractions of the M. alpina cDNA were packaged separately to yield libraries with different average-sized inserts. A "full-length" library contains approximately 3 x 10⁶ clones with an average insert size of 1.77 kb. The

"sequencing-grade" library contains approximately 6 x 10⁵ clones with an average insert size of 1.1 kb. Example 2

Isolation of a Δ6-desaturase Nucleotide Sequence from Mortierella Alpina

A nucleic acid sequence from a partial cDNA clone, Ma524, encoding a Δ6 fatty acid desaturase from Mortierella alpina was obtained by random sequencing of clones from the M. alpina cDNA sequencing grade library described in Example 1. cDNA-containing plasmids were excised as follows:

Five μl of phage were combined with 100 μl of E. coli DHIOB(ZIP) grown in ECLB plus 10 μg/ l kanamycin, 0.2% maltose, and 10 mM MgSO₄ and incubated at 37 degrees for 15 minutes. 0.9 ml SOC was added and 100 μl of the bacteria immediately plated on each of 10 ECLB + 50 μg Pen plates. No

45 minute recovery time was needed. The plates were incubated overnight at 37°. Colonies were picked into ECLB + 50 μg Pen media for overnight cultures to be used for making glycerol stocks and miniprep DNA. An aliquot of the culture used for the miniprep is stored as a glycerol stock. Plating on ECLB + 50 μg Pen/ml resulted in more colonies and a greater proportion of colonies containing inserts than plating on 100 μg/ml Pen.

Random colonies were picked and plasmid DNA purified using Qiagen miniprep kits. DNA sequence was obtained from the 5' end of the cDNA insert and compared to the National Center for Biotechnology Information (NCBI) nonredundant database using the BLASTX algorithm. Ma524 was identified as a putative desaturase based on DNA sequence homology to previously identified desaturases.

A full-length cDNA clone was isolated from the M. alpina full-length library and designed pCGN5532. The cDNA is contained as a 1617 bp insert in the vector pZLl (BRL) and, beginning with the first ATG, contains an open reading frame encoding 457 amino acids. The three conserved "histidine boxes" known to be conserved among membrane-bound desaturases (Okuley, et al. (1994) The Plant Cell 6: 147-158) were found to be present at amino acid positions 172-176, 209-213, and 395-399 (see Figure 3). As with other membrane-bound Δ6-desaturases the final HXXHH histidine box motif was found to be QXXHH. The amino acid sequence of Ma524 was found to display significant homology to a portion of a Caenorhabditis elegans cosmid, WO6D2.4, a cytochrome b5/desaturase fusion protein from sunflower, and the Synechocystis and Spirulina Δ 6-desaturases. In addition, Ma524 was shown to have homology to the borage Δ6-desaturase amino sequence (PCT publication W) 96/21022). Ma524 thus appears to encode a Δ6-desaturase that is related to the borage and algal Δ6-desaturases. The peptide sequences are shown as SEQ ID NO:5 - SEQ ID NO:l l. The amino terminus of the encoded protein was found to exhibit significant homology to cytochrome b5 proteins. The Mortierella cDNA clone appears to represent a fusion between a cytochrome b5 and a fatty acid desaturase. Since cytochrome b5 is believed to function as the electron donor for membrane-bound desaturase enzymes, it is possible that the N-terminal cytochrome b5 domain of this desaturase protein is involved in its function.

This may be advantageous when expressing the desaturase in heterologous systems for PUFA production. However, it should be noted that, although the amino acid sequences of Ma524 and the borage Δ6 were found to contain regions of homology, the base compositions of the cDNAs were shown to be significantly different. For example, the borage cDNA was shown to have an overall base composition of 60 % A/T, with some regions exceeding 70 %, while Ma524 was shown to have an average of 44 % A/T base composition, with no regions exceeding 60 %. This may have implications for expressing the cDNAs in microorganisms or animals which favor different base compositions. It is known that poor expression of recombinant genes can occur when the host prefers a base composition different from that of the introduced gene. Mechanisms for such poor expression include decreased stability, cryptic splice sites, and or translatability of the mRNA and the like. Example 3

Identification of Δ6-desaturases Homologous to the Mortierella alpina Δ6-desaturase

Nucleic acid sequences that encode putative Δ6-desaturases were identified through a BLASTX search of the Expressed Sequence Tag ("EST") databases through NCBI using the Ma524 amino acid sequence. Several sequences showed significant homology. In particular, the deduced amino acid sequence of two Arabidopsis thaliana sequences, (accession numbers F13728 and T42806) showed homology to two different regions of the deduced amino acid sequence of Ma524. The following PCR primers were designed:

ATTS4723-FOR (complementary to F13728) SEQ ID NO: 13 5' CUACUACUACUAGGAGTCCTCTACGGTGTTTTG and T42806-REV (complementary to T42806) SEQ ID NO: 14 5' CAUCAUCAUCAUATGATGCTCAAGCTGAAACTG. Five μg of total RNA isolated from developing siliques of Arabidopsis thaliana was reverse transcribed using BRL Superscript RTase and the primer TSyn (5'-CCAAGCTTCTGCAGGAGCTCTTTTTTTTTTTTTTT-3^,) and is shown as SEQ ID NO: 12. PCR was carried out in a 50 μl volume containing: template derived from 25 ng total RNA, 2 pM each primer, 200 μM each deoxyribonucleotide triphosphate, 60 mM Tris-Cl, pH 8.5, 15 mM (NH₄)₂SO₄,

2 mM MgCl₂, 0.2 U Taq Polymerase. Thermocycler conditions were as follows: 94 degrees for 30 sec, 50 degrees for 30 sec, 72 degrees for 30 sec. PCR was continued for 35 cycles followed by an additional extension at 72 degrees for 7 minutes. PCR resulted in a fragment of approximately -750 base pairs which was subcloned, named 12-5, and sequenced. Each end of this fragment was formed to correspond to the Arabidopsis ESTs from which the PCR primers were designed. The putative amino acid sequence of 12-5 was compared to that of Ma524, and ESTs from human (W28140), mouse (W53753), and C. elegans (R05219) (see Figure 4). Homology patterns with the Mortierella Δ6- desaturase indicate that these sequences represent putative desaturase polypeptides. Based on this experiment approach, it is likely that the full-length genes can be cloned using probes based on the EST sequences. Following the cloning, the genes can then be placed into expression vectors, expressed in host cells, and their specific Δ6- or other desaturase activity can be determined as described below.

Example 4

Isolation of a Δ12-desaturase Nucleotide Sequence from Mortierella alpina

Based on the fatty acids it accumulates, it seemed probable that Mortierella alpina has an ω6 type desaturase. The ω6-desaturase is responsible for the production of linoleic acid (18:2) from oleic acid (18:1). Linoleic acid

(18:2) is a substrate for a Δ6-desaturase. This experiment was designed to determine if Mortierella alpina has a Δ12-desaturase polypeptide, and if so, to identify the corresponding nucleotide sequence.

A random colony from the M. alpina sequencing grade library, Ma648, was sequenced and identified as a putative desaturase based on DNA sequence homology to previously identified desaturases, as described for Ma524 (see Example 2). The nucleotide sequence is shown in SEQ ID NO: 13. The peptide sequence is shown in SEQ ID NO:4. The deduced amino acid sequence from the 5' end of the Ma648 cDNA displays significant homology to soybean microsomal <x>6 (Δ12) desaturase (accession #L43921) as well as castor bean oleate 12-hydroxylase (accession #U22378). In addition, homology was observed when compared to a variety of other ω6 (Δ12) and ω3 (Δ15) fatty acid desaturase sequences. Example 5

Expression of M. alpina Desaturase Clones in Baker's Yeast

Yeast Transformation

Lithium acetate transformation of yeast was performed according to standard protocols (Methods in Enzymology, Vol. 194, p. 186-187, 1991).

Briefly, yeast were grown in YPD at 30°C. Cells were spun down, resuspended in TE, spun down again, resuspended in TE containing 100 mM lithium acetate, spun down again, and resuspended in TE/lithium acetate. The resuspended yeast were incubated at 30°C for 60 minutes with shaking. Carrier DNA was added., and the yeast were aliquoted into tubes. Transforming DNA was added, and the tubes were incubated for 30 min. at 30°C. PEG solution (35% (w/v) PEG 4000, 100 mM lithium acetate, TE pH7.5) was added followed by a 50 min. incubation at 30°C. A 5 min. heat shock at 42°C was performed, the cells were pelleted, washed with TE, pelleted again and resuspended in TE. The resuspended cells were then plated on selective media.

Desaturase Expression in Transformed Yeast cDNA clones from Mortierella alpina were screened for desaturase activity in baker's yeast. A canola Δ15-desaturase (obtained by PCR using 1^st strand cDNA from Brassica napus cultivar 212/86 seeds using primers based on the published sequence (Arondel et al. Science 258: 1353-1355)) was used as a positive control. The Δ15-desaturase gene and the gene from cDNA clones Ma524 and Ma648 were put in the expression vector pYES2 (Invitrogen), resulting in plasmids pCGR-2, pCGR-5 and pCGR-7, respectively. These plasmids were transfected into S. cerevisiae yeast strain 334 and expressed after induction with galactose and in the presence of substrates that allowed detection of specific desaturase activity. The control strain was S. cerevisiae strain 334 containing the unaltered pYES2 vector. The substrates used, the products produced and the indicated desaturase activity were: DGLA (conversion to ARA would indicate Δ5-desaturase activity), linoleic acid (conversion to GLA would indicate Δ6-desaturase activity; conversion to ALA would indicate Δ15- desaturase activity), oleic acid (an endogenous substrate made by S. cerevisiae, conversion to linoleic acid would indicate Δ12-desaturase activity, which S. cerevisiae lacks), or ARA (conversion to EPA would indicate Δ17-desaturase activity).

Cultures were grown for 48-52 hours at 15°C in the presence of a particular substrate. Lipid fractions were extracted for analysis as follows: Cells were pelleted by centrifugation, washed once with sterile ddH 0, and repelleted. Pellets were vortexed with methanol; chloroform was added along with tritridecanoin (as an internal standard). The mixtures were incubated for at least one hour at room temperature or at 4°C overnight. The chloroform layer was extracted and filtered through a Whatman filter with one gram of anhydrous sodium sulfate to remove particulates and residual water. The organic solvents were evaporated at 40°C under a stream of nitrogen. The extracted lipids were then derivatized to fatty acid methyl esters (FAME) for gas chromatography analysis (GC) by adding 2 ml of 0.5 N potassium hydroxide in methanol to a closed tube. The samples were heated to 95°C to 100°C for 30 minutes and cooled to room temperature. Approximately 2 ml of 14 % boron trifluoride in methanol was added and the heating repeated. After the extracted lipid mixture cooled, 2 ml of water and 1 ml of hexane were added to extract the FAME for analysis by GC. The percent conversion was calculated by dividing the product produced by the sum of (the product produced and the substrate added) and then multiplying by 100. To calculate the oleic acid percent conversion, as no substrate was added, the total linoleic acid produced was divided by the sum of oleic acid and linoleic acid produced, then multiplying by 100. The desaturase activity results are provided in Table 1 below. Table 1 M. alpina Desaturase Expression in Baker's Yeast

% CONVERSION

CLONE ENZYME ACTIVITY OF SUBSTRATE pCGR-2 Δ6 0 (18:2 to 18:3 6)

(canola Δ15 Δ15 16.3 (18:2 to l8:3w3) desaturase) Δ5 2.0 (20:3 to 20:4w6)

Δ17 2.8 (20:4 to 20:5w3)

Δ12 1.8 (18:1 to 18:2 6)

pCGR-5 Δ6 6.0

(M. alpina Δ15 0

Ma524 Δ5 2.1

Δ17 0

Δ12 3.3

pCGR-7 Δ6 0

(M. alpina Δ15 3.8

Ma648 Δ5 2.2

Δ17 0

Δ12 63.4

The Δ15-desaturase control clone exhibited 16.3% conversion of the substrate. The pCGR-5 clone expressing the Ma524 cDNA showed 6% conversion of the substrate to GLA, indicating that the gene encodes a Δ6- desaturase. The pCGR-7 clone expressing the Ma648 cDNA converted 63.4% conversion of the substrate to LA, indicating that the gene encodes a Δ12- desaturase. The background (non-specific conversion of substrate) was between 0-3% in these cases. We also found substrate inhibition of the activity by using different concentrations of the substrate. When substrate was added to 100 μM, the percent conversion to product dropped compared to when substrate was added to 25 μM (see below). Additionally, by varying the substrate concentration between 5 μM and 200 μM, conversion ratios were found to range between about 5% to about 75% greater. These data show that desaturases with different substrate specificities can be expressed in a heterologous system and used to produce poly-unsaturated long chain fatty acids.

Table 2 represents fatty acids of interest as a percent of the total lipid extracted from the yeast host S. cerevisiae 334 with the indicated plasmid. No glucose was present in the growth media. Affinity gas chromatography was used to separate the respective lipids. GC/MS was employed to verify the identity of the product(s). The expected product for the B. napus Δ15-desaturase, α- linolenic acid, was detected when its substrate, linoleic acid, was added exogenously to the induced yeast culture. This finding demonstrates that yeast expression of a desaturase gene can produce functional enzyme and detectable amounts of product under the current growth conditions. Both exogenously added substrates were taken up by yeast, although slightly less of the longer chain PUFA, dihomo-γ-linolenic acid (20:3), was incorporated into yeast than linoleic acid (18:2) when either was added in free form to the induced yeast cultures, γ- linolenic acid was detected when linoleic acid was present during induction and expression of S. cerevisiae 334 (pCGR-5). The presence of this PUFA demonstrates Δ6-desaturase activity from pCGR-5 (MA524). Linoleic acid, identified in the extracted lipids from expression of S. cerevisiae 334 (pCGR-7), classifies the cDNA MA648 from M. alpina as the Δ12-desaturase.

Table 2 Fatty Acid as a Percentage of Total Lipid Extracted from Yeast

100 μM substrate added

* 18:1 is an endogenous fatty acid in yeast

Key To Tables 18:l=oleic acid 18:2=linoleic acid α-18:3= -linolenic acid γ-18:3=γ-linolenic acid 18:4=stearidonic acid 20:3=dihomo-γ-linolenic acid 20:4=arachidonic acid

Example 6

Optimization of Culture Conditions

Table 3A shows the effect of exogenous free fatty acid substrate concentration on yeast uptake and conversion to fatty acid product as a percentage of the total yeast lipid extracted. In all instances, low amounts of exogenous substrate (1-10 μM) resulted in low fatty acid substrate uptake and product formation. Between 25 and 50 μM concentration of free fatty acid in the growth and induction media gave the highest percentage of fatty acid product formed, while the 100 μM concentration and subsequent high uptake into yeast appeared to decrease or inhibit the desaturase activity. The amount of fatty acid substrate for yeast expressing Δ12-desaturase was similar under the same growth conditions, since the substrate, oleic acid, is an endogenous yeast fatty acid. The use of -linolenic acid as an additional substrate for pCGR-5 (Δ6) produced the expected product, stearidonic acid (Table 3A). The feedback inhibition of high fatty acid substrate concentration was well illustrated when the percent conversion rates of the respective fatty acid substrates to their respective products were compared in Table 3B. In all cases, 100 μM substrate concentration in the growth media decreased the percent conversion to product. The uptake of α-linolenic was comparable to other PUFAs added in free form, while the Δ6-desaturase percent conversion, 3.8-17.5%, to the product stearidonic acid was the lowest of all the substrates examined (Table 3B). The effect of media, such as YPD (rich media) versus minimal media with glucose on the conversion rate of Δ12-desaturase was dramatic. Not only did the conversion rate for oleic to linoleic acid drop, (Table 3B) but the percent of linoleic acid formed also decreased by 11% when rich media was used for growth and induction of yeast desaturase Δ12 expression (Table 3 A). The effect of media composition was also evident when glucose was present in the growth media for Δ6-desaturase, since the percent of substrate uptake was decreased at 25 μM (Table 3A). However, the conversion rate remained the same and percent product formed decreased for Δ6-desaturase for in the presence of glucose.

Table 3A

Effect of Added Substrate on the Percentage of Incorporated

Substrate and Product Formed in Yeast Extracts

Table 3B

Effect of Substrate Concentration in Media on the Percent Conversion of Fatty Acid Substrate to Product in Yeast Extracts

0 no glucose in media

⁺ Yeast peptone broth (YPD)

* 18:1 is an endogenous yeast lipid sub. is substrate concentration

ND (not done)

Table 4 shows the amount of fatty acid produced by a recombinant desaturase from induced yeast cultures when different amounts of free fatty acid substrate were used. Fatty acid weight was determined since the total amount of lipid varied dramatically when the growth conditions were changed, such as the presence of glucose in the yeast growth and induction media. To better determine the conditions when the recombinant desaturase would produce the most PUFA product, the quantity of individual fatty acids were examined. The absence of glucose dramatically reduced by three fold the amount of linoleic acid produced by recombinant Δ12-desaturase. For the Δ12-desaturase the amount of total yeast lipid was decreased by almost half in the absence of glucose. Conversely, the presence of glucose in the yeast growth media for Δ6- desaturase drops the γ-linolenic acid produced by almost half, while the total amount of yeast lipid produced was not changed by the presence/absence of glucose. This points to a possible role for glucose as a modulator of Δ6- desaturase activity.

Table 4 Fatty Acid Produced in μg from Yeast Extracts

0 no glucose in media sub. is substrate concentration

ND (not done)

* 18:1, the substrate, is an endogenous yeast lipid

Example 7

Distribution of PUFAs in Yeast Lipid Fractions

Table 5 illustrates the uptake of free fatty acids and their new products formed in yeast lipids as distributed in the major lipid fractions. A total lipid extract was prepared as described above. The lipid extract was separated on

TLC plates, and the fractions were identified by comparison to standards. The bands were collected by scraping, and internal standards were added. The fractions were then saponified and methylated as above, and subjected to gas chromatography. The gas chromatograph calculated the amount of fatty acid by comparison to a standard. The phospholipid fraction contained the highest amount of substrate and product PUFAs for Δ6-desaturase activity. It would appear that the substrates are accessible in the phospholipid form to the desaturases. Table 5

Fatty Acid Distribution in Various Yeast Lipid Fractions in μg

SC = 5. cerevisiae (plasmid)

Example 8

Further Culture Optimization and Coexpression of Δ6 and Δ12-desaturases

This experiment was designed to evaluate the growth and induction conditions for optimal activities of desaturases in Saccharomyces cerevisiae. A Saccharomyces cerevisiae strain (SC334) capable of producing γ-linolenic acid (GLA) was developed, to assess the feasibility of production of PUFA in yeast.

The genes for Δ6 and Δ12-desaturases from M. alpina were coexpressed in SC334. Expression of Δ12-desaturase converted oleic acid (present in yeast) to linoleic acid. The linoleic acid was used as a substrate by the Δ6-desaturase to produce GLA. The quantity of GLA produced ranged between 5-8% of the total fatty acids produced in SC334 cultures and the conversion rate of linoleic acid to γ-linolenic acid ranged between 30% to 50%. The induction temperature was optimized, and the effect of changing host strain and upstream promoter sequences on expression of Δ6 and Δ12 (MA 524 and MA 648 respectively) desaturase genes was also determined. Plasmid Construction

The cloning of pCGR5 as well as pCGR7 has been discussed above. To construct pCGR9a and pCGR9b, the Δ6 and Δ12-desaturase genes were amplified using the following sets of primers. The primers pRDS 1 and 3 had Xhol site and primers pRDS2 and 4 had Xbal site (indicated in bold). These primer sequences are presented as SEQ ID NO: 15-18.

I. Δ6-desaturase amplification primers a. pRDS1 TAC CAA CTC GAG AAA ATG GCT GCT GCT CCC AGT GTG AGG b. pRDS2 AACTGATCTAGATTACTG CGC CTTACCCAT

CTT GGA GGC

II. Δ12-desaturase amplification primers a. pRDS3 TAC CAA CTC GAG AAA ATG GCA CCT CCC AAC ACT ATC GAT b. pRDS4 AAC TGA TCTAGA TTA CTT CTT GAA AAA GAC

CAC GTC TCC

The pCGR5 and pCGR7 constructs were used as template DNA for amplification of Δ6 and Δ12-desaturase genes, respectively. The amplified products were digested with Xbal and Xhol to create "sticky ends". The PCR amplified Δ6-desaturase with Xhol-Xbal ends as cloned into pCGR7, which was also cut with Xho-1-Xbal. This procedure placed the Δ6-desaturase behind the Δ12-desaturase, under the control of an inducible promoter GAL This construct was designated pCGR9a. Similarly, to construct pCGR9b, the Δ12- desaturase with Xhol-Xbal ends was cloned in the Xhol-Xbal sites of pCGR5. In pCGR9b the Δ12-desaturase was behind the Δ6-desaturase gene, away from the GAL promoter.

To construct pCGRlO, the vector pRS425, which contains the constitutive Glyceraldehyde 3-Phosphate Dehydrogenase (GPD) promoter, was digested with BamHI and pCGR5 was digested with BamHl-Xhol to release the Δ6-desaturase gene. This Δ6-desaturase fragment and BamHI cut pRS425 were filled using Klenow Polymerase to create blunt ends and ligated, resulting in pCGRlOa and pCGRlOb containing the Δ6-desaturase gene in the sense and antisense orientation, respectively. To construct pCGRl 1 and pCGR12, the Δ6 and Δ12-desaturase genes were isolated from pCGR5 and pCGR7, respectively, using an EcoRl-XhoI double digest. The EcoRI -Xhol fragments of Δ6 and Δ12- desaturases were cloned into the pYX242 vector digested with EcoRl-Xhol. The p YX242 vector has the promoter of TPl ( a yeast housekeeping gene), which allows constitutive expression. Yeast Transformation and Expression

Different combinations of pCGR5, pCGR7, pCGR9a, pCGR9b, pCGRlOa, pCGRl 1 and pCGR12 were introduced into various host strains of Saccharomyces cerevisiae. Transformation was done using PEG/LiAc protocol (Methods in Enzymology Vol. 194 (1991): 186-187). Transformants were selected by plating on synthetic media lacking the appropriate amino acid. The pCGR5, pCGR7, pCGR9a and pCGR9b can be selected on media lacking uracil. The pCGRlO, pCGRl 1 and pCGR12 constructs can be selected on media lacking leucine. Growth of cultures and fatty acid analysis was performed as in Example 5 above. Production of GLA

Production of GLA requires the expression of two enzymes ( the Δ6 and Δ12-desaturases), which are absent in yeast. To express these enzymes at optimum levels the following constructs or combinations of constructs, were introduced into various host strains: 1) pCGR9a/SC334

2) pCGR9b/SC334

3) pCGR10a and pCGR7/SC334

4) pCGRl l and pCGR7/SC334

5) pCGR12 and pCGR5/SC334 6) pCGR10a and pCGR7/DBY746

7) pCGR10a and pCGR7/DBY746

The pCGR9a construct has both the Δ6 and Δ12-desaturase genes under the control of an inducible GAL promoter. The SC334 host cells transformed with this construct did not show any GLA accumulation in total fatty acids (Fig.

6A and B, lane 1). However, when the Δ6 and Δ12-desaturase genes were individually controlled by the GAL promoter, the control constructs were able to express Δ6- and Δ12-desaturase, as evidenced by the conversion of their respective substrates to products. The Δ12-desaturase gene in pCGR9a was expressed as evidenced by the conversion of 18:1 ω9 to 18:2ω6 in pCGR9a/SC334, while the Δ6-desaturase gene was not expressed/active, because the 18:2ω6 was not being converted to 18:3ω6 (Fig. 6A and B, lane 1).

The pCGR9b construct also had both the Δ6 and Δ12-desaturase genes under the control of the GAL promoter but in an inverse order compared to pCGR9a. In this case, very little GLA (< 1 %) was seen in pCGR9b/SC334 cultures. The expression of Δ12-desaturase was also very low, as evidenced by the low percentage of 18:2ω6 in the total fatty acids (Fig. 6A and B, lane 1).

To test if expressing both enzymes under the control of independent promoters would increase GLA production, the Δ6-desaturase gene was cloned into the pRS425 vector. The construct of pCGRlOa has the Δ6-desaturase in the correct orientation, under control of constitutive GPD promoter. The pCGRlOb has the Δ6-desaturase gene in the inverse orientation, and serves as the negative control. The pCGR10a/SC334 cells produced significantly higher levels of GLA (5% of the total fatty acids, Fig. 6, lane 3), compared to pCGR9a. Both the Δ6 and Δ12-desaturase genes were expressed at high level because the conversion of 18:lω9- 18:2ω6 was 65%, while the conversion of 18:2ω6 — > 18:3ω6 (Δ6-desaturase) was 30% (Fig. 6, lane 3). As expected, the negative control pCGR10b/SC334 did not show any GLA.

To further optimize GLA production, the Δ6 and Δ12 genes were introduced into the p YX242 vector, creating pCGR 11 and pCGR 12 respectively. The pYX242 vector allows for constitutive expression by the TPl promoter (Alber, T. and Kawasaki, G. (1982). J. Mol & Appl. Genetics 1: 419). The introduction of pCGRl 1 and pCGR7 in SC334 resulted in approximately 8% of GLA in total fatty acids of SC334. The rate of conversion of 18: lω9→- 18:2ω6 and 18:2ω6 → 18:3ω6 was approximately 50% and 44% respectively (Fig. 6A and B, lane 4). The presence of pCGR12 and pCGR5 in SC334 resulted in 6.6% GLA in total fatty acids with a conversion rate of approximately 50% for both 18:lω9 to 18:2ω6 and 18:2ω6 to 18:3ω6, respectively (Fig. 6A and B, lane 5). Thus although the quantity of GLA in total fatty acids was higher in the pCGRl l/pCGR7 combination of constructs, the conversion rates of substrate to product were better for the pCGR12/pCGR5 combination.

To determine if changing host strain would increase GLA production, pCGRlOa and pCGR7 were introduced into the host strain BJ1995 and DBY746 (obtained from the Yeast Genetic Stock Centre, 1021 Donner

Laboratory, Berkeley, CA 94720. The genotype of strain DBY746 is Matα, his3-Δl, leu2-3, leu2-l 12, ura3-32, trpl-289, gal). The results are shown in Fig. 7. Changing host strain to BJ1995 did not improve the GLA production, because the quantity of GLA was only 1.31% of total fatty acids and the conversion rate of 18:lω9 -» 18:2ω6 was approximately 17% in BJ1995. No

GLA was observed in DBY746 and the conversion of 18: lω9 -> 18:2ω6 was very low (<1% in control) suggesting that a cofactor required for the expression of Δ12-desaturase might be missing in DB746 (Fig. 7, lane 2).

To determine the effect of temperature on GLA production, SC334 cultures containing pCGRlOa and pCGR7 were grown at 15°C and 30°C.

Higher levels of GLA were found in cultures grown and induced at 15°C than those in cultures grown at 30°C (4.23% vs. 1.68%). This was due to a lower conversion rate of 18:2ω6 → 18:3ω6 at 30°C (11.6% vs. 29% in 15°C) cultures, despite a higher conversion of 18:lω9 → 18:2ω6 (65% vs. 60% at 30°C (Fig. 8). These results suggest that Δ12- and Δ6-desaturases may have different optimal expression temperatures. Of the various parameters examined in this study, temperature of growth, yeast host strain and media components had the most significant impact on the expression of desaturase, while timing of substrate addition and concentration of inducer did not significantly affect desaturase expression. These data show that two DNAs encoding desaturases that can convert

LA to GLA or oleic acid to LA can be isolated from Mortierella alpina and can be expressed, either individually or in combination, in a heterologous system and used to produce poly-unsaturated long chain fatty acids. Exemplified is the production of GLA from oleic acid by expression of Δ12- and Δ6-desaturases in yeast.

Example 9

Expression of M. alpina D12- and D6-Desaturase genes in Insect Cells

Insect cells were used as another eukaryotic host to express M. alpina Δ12- and Δ6 -desaturase genes. Here, the M. alpina Δ12- and Δ6 -desaturases have been cloned into a baculovirus expression vector and analyzed for the production of LC-PUFAs. Insect cells are known to have no endogenous PUFA desaturase activities. Therefore, this system is suitable for expression and characterization of the recombinant desaturases. The fragment containing the Δ6-desaturase gene (pCGR5, see Example

5) was PCR amplified using Expand High Fidelity PCR System (Boehringer Mannheim, Corp., Indianapolis, IN) and a set of primers containing appropriate restriction sites. To amplify D6 cDNA, the forward primer used was designated as RO650 (5'- TATCCGGAATTCGCCGCCACCATGGCTGCTGCTCCCAGTG), SEQ ID

NO:41 which corresponded to the sense strand of D6 and included an EcoRI site upstream of the ATG. The reverse primer was designated as RO193 (5 - AACTGCCTCGAGTTACTGCGCCTTACCCATCTTGGAGGC) SEQ ID NO:42 which corresponded to the antisense strand at the 3' end of the Δ6 cDNA, and had an Xhol site after the stop codon. The PCR reaction, in a final volume of 100 μl, was carried out for 30 cycles in temperature conditions of 45 seconds at 94°C, 45 seconds at 55°C and 2 min at 72°C. The Δ12 cDNA was obtained by digesting the plasmid pCGR7 (See Example 5) which contained Δ12 cDNA cloned in the pYES2 vector (Invitrogen, Carlsbad, CA), with EcoRI and Xhol. The Δ6 PCR amplified product restricted with EcoRI/XhoI as well as the Δ12 insert were analyzed by agarose-gel electrophoresis, gel purified, then ligated into pFastBacl baculovirus donor plasmid (Gibco-BRL, Gaithersburg, MD) at the EcoRI/XhoI sites. The respective baculovirus clones were designated as pJPB6 for the Δ6-desaturase, and pJPB12 for the Δ12-desaturase. This pFastBacl vector contains an expression cassette which has a polyhedrin promoter, a SV40 polyadenylation signal, and a gentamycin resistance marker.

The initial transformations were done in XL1 blue cells (Invitrogen, Carlsbad, CA). Positive clones were then transformed into E. coli DHlOBac (Gibco-BRL, Gaithersburg, MD) which contains the baculovirus genome. The positive clones were selected by blue white screening in which white colonies contain the recombinant bacmid. White colonies were then picked for bacmid DNA isolation. DNA was isolated using a Qiagen plasmid isolation kit (Qiagen Inc., Valencia, CA), specific for DNA over 135 kb long. The recombinant DNA bacmids were analyzed on a 0.6% agarose gel to confirm the presence of the high molecular weight DNA. PCR analysis, using pUC/M13 primers (forward

S'-TGTAAAACGACGGCCAGT (SEQ ID NO:43) and reverse 5'- GAAACAGCTATGACCATG) SEQ ID NO:44 was also performed to confirm the correct insert size for the desaturase cDNAs within the bacmid.

The Sf9 insect cells (Spodoptera frugiperda) were used for the recombinant bacmid DNA transfection. These cells were grown in serum free media. Transfection was carried out according to the CellFECTIN protocol (Gibco-BRL, Gaithersburg, MD). The recombinant virus was recovered by collecting the supernatant at 72 hours post-transfection. Plaque assay was performed on the supernatants to determine the titer of recovered recombinant virion particles. Each recombinant viral stock was made for the expression studies. All infections with the recombinant viruses were done during the mid- logarithmic growth phase of the Sf9's and infected at 5 MOI (Mutiplicity of Infection). To analyze the activity of the expressed desaturase genes, Sf9 cells were plated at a concentration of 1x106 cells/well in a 6-well plate and infected with lOOμl of the recombinant virus stock (approximately 5 MOI). The appropriate substrate was supplemented at the time of infection, at a final concentration of 25 μM. A mock infected Sf9, as well as cells infected with a recombinant virus containing the GusA gene, were used as negative controls in each experiment. The medium was collected 48 hours post infection and saved. The cells were collected and submitted for lipid analysis. For fatty acid analysis, cell pellets were vortexed with 6 ml of methanol, followed by the addition of 12 ml of chloroform and tridecanoin (as internal standard). The mixtures were incubated for at least one hour at room temperature or at 4°C overnight. The chloroform layer was extracted and filtered through a Whatman filter with one gram of anhydrous sodium sulfate to remove particulates and residual water. The organic solvents were evaporated at

40°C under a stream of nitrogen. The extracted lipids were derivatized to fatty acid methyl esters (FAME) for gas chromatography analysis (GC) by adding 2 ml of 0.5N potassium hydroxide in methanol to a closed tube. The samples were heated at 95 to 100°C for 30 minutes and cooled to room temperature. Approximately 2 ml of the 14% boron triflouride in methanol was added and the heating repeated. After the extracted lipid mixture cooled, 2 ml of water and 1 ml of hexane were added to extract the FAME for GC analysis. The percent conversion was calculated by dividing the product produced by the sum of (the product produced and the substrate) and then multiplying by 100. The fatty acid profile of insect cells after expressing the recombinant M. alpina Δ12-desaturase is summarized in Table 6A. The monounsaturated fatty acid, oleic acid (OA, 18:ln-9) is naturally present in insect cells, therefore no substrate was added. By expressing M. alpina Δ12-desaturase, the amount of LA produced by the Δ12-desaturase appeared to be 24.6% with respect to only 0.127% in the control. Thus, the Δ12-desaturase is capable of converting the

OA to LA 133 fold over the control and has a conversion rate of 48.3%. The fatty acid profile of insect cells after expressing the M. alpina Δ6- desaturase is summarized in Table 6B. The insect cells were supplemented with linoleic acid (LA, 18:2n-6), at a concentration of 25 μM, at the time of infection. The cells were then pelleted and analyzed for fatty acid content. The conversion of the added substrate, LA, to γ-linolenic (GLA, 18:3n-6) was monitored. GLA was detected in the presence of expressed Δ6-desaturase enzyme. The Δ6-desaturase in the baculovirus system was able to produce 9 fold more GLA (18:3n-6) than the control at a conversion of 0.25%. The fatty acid amounts of GLA produced were 0.045% by Δ6-desaturase and 0.001% by the control, respectively.

These data show that the Δ12- and Δ6-desaturases can be expressed in another eukaryotic host (insect cells) in biologically active forms, as demonstrated by the production of LA by the Δ12-desaturase and GLA by the Δ6-desaturase

Table 6

Example 10

Identification of Homologues to M. alpina Δ5 and Δ6 desaturases

A nucleic acid sequence that encodes a putative Δ5 desaturase was identified through a TBLASTN search of the expressed sequence tag databases through NCBI using amino acids 100-446 of Ma29 as a query. The truncated portion of the Ma29 sequence was used to avoid picking up homologies based on the cytochrome b5 portion at the N-terminus of the desaturase. The deduced amino acid sequence of an est from Dictyostelium discoideum (accession # C25549) shows very significant homology to Ma29 and lesser, but still significant homology to Ma524. The DNA sequence is presented as SEQ ID

NO: 19. The amino acid sequence is presented as SEQ ID NO:20.

Example 11

Identification of M. alpina Δ5 and Δ6 homologues in other PUFA-producing organisms

To look for desaturases involved in PUFA production, a cDNA library was constructed from total RNA isolated from Phaeodactylum tricornutum. A plasmid-based cDNA library was constructed in pSPORTl (GIBCO-BRL) following manufacturer's instructions using a commercially available kit (GIBCO-BRL). Random cDNA clones were sequenced and nucleic acid sequences that encode putative Δ5 or Δ6 desaturases were identified through

BLAST search of the databases and comparison to Ma29 and Ma524 sequences.

One clone was identified from the Phaeodactylum library with homology to Ma29 and Ma524; it is called 144-011-B 12. The DNA sequence is presented as SEQ ID NO:21. The amino acid sequence is presented as SEQ ID NO:22. Example 12

To look for desaturases involved in PUFA production, a cDNA library was constructed from total RNA isolated from Schizochytrium species. A plasmid-based cDNA library was constructed in pSPORTl (GIBCO-BRL) following manufacturer's instructions using a commercially available kit (GIBCO-BRL). Random cDNA clones were sequenced and nucleic acid sequences that encode putative Δ5 or Δ6 desaturases were identified through BLAST search of the databases and comparison to Ma29 and Ma524 sequences.

One clone was identified from the Schizochytrium library with homology to Ma29 and Ma524; it is called 81-23-C7. This clone contains a -1 kb insert. Partial sequence was obtained from each end of the clone using the universal forward and reverse sequencing primers. The DNA sequence from the forward primer is presented as SEQ ID NO:23. The peptide sequence is presented as SEQ ID NO:24. The DNA sequence from the reverse primer is presented as SEQ ID NO:25. The amino acid sequence from the reverse primer is presented as SEQ ID NO:26.

Example 13

Human Desaturase Gene Sequences

Human desaturase gene sequences potentially involved in long chain polyunsaturated fatty acid biosynthesis were isolated based on homology between the human cDNA sequences and Mortierella alpina desaturase gene sequences. The three conserved "histidine boxes" known to be conserved among membrane-bound desaturases were found. As with some other membrane-bound desaturases the final HXXHH histidine box motif was found to be QXXHH. The amino acid sequence of the putative human desaturases exhibited homology to M. alpina Δ5, Δ6, Δ9, and Δ12 desaturases. The M. alpina Δ5 desaturase and Δ6 desaturase cDNA sequences were used to search the LifeSeq database of Incyte Pharmaceuticals, Inc., Palo Alto, California 94304. The Δ5 desaturase sequence was divided into fragments; 1) amino acid no. 1-150, 2) amino acid no. 151-300, and 3) amino acid no. 301- 446. The Δ6 desaturase sequence was divided into three fragments; 1) amino acid no. 1-150, 2) amino acid no. 151-300, and 3) amino acid no. 301-457. These polypeptide fragments were searched against the database using the "tblastn" algorithm. This algorithm compares a protein query sequence against a nucleotide sequence database dynamically translated in all six reading frames (both strands).

The polypeptide fragments 2 and 3 of M. alpina Δ5 and Δ6 have homologies with the ClonelD sequences as outlined in Table 7. The ClonelD represents an individual sequence from the Incyte LifeSeq database. After the "tblastn" results have been reviewed, Clone Information was searched with the default settings of Stringency of >=50, and Productscore <=100 for different

ClonelD numbers. The Clone Information Results displayed the information including the ClusterlD, ClonelD, Library, HitID, Hit Description. When selected, the ClusterlD number displayed the clone information of all the clones that belong in that ClusterlD. The Assemble command assembles all of the ClonelD which comprise the ClusterlD. The following default settings were used for GCG (Genetics Computer Group, University of Wisconsin Biotechnology Center, Madison, Wisconsin 53705) Assembly:

Word Size: 7 Minimum Overlap: 14

Stringency: 0.8

Minimum Identity: 14

Maximum Gap: 10

Gap Weight: 8 Length Weight: 2 GCG Assembly Results displayed the contigs generated on the basis of sequence information within the ClonelD. A contig is an alignment of DNA sequences based on areas of homology among these sequences. A new sequence (consensus sequence) was generated based on the aligned DNA sequences within a contig. The contig containing the ClonelD was identified, and the ambiguous sites of the consensus sequence was edited based on the alignment of the ClonelDs (see SEQ ID NO:27 - SEQ ID NO:32) to generate the best possible sequence. The procedure was repeated for all six ClonelD listed in Table 6. This produced five unique contigs. The edited consensus sequences of the 5 contigs were imported into the Sequencher software program (Gene Codes Corporation, Ann Arbor, Michigan 48 105). These consensus sequences were assembled. The contig 2511785 overlaps with contig 3506132, and this new contig was called 2535 (SEQ ID NO:33). The contigs from the Sequencher program were copied into the Sequence Analysis software package of GCG.

Each contig was translated in all six reading frames into protein sequences. The M. alpina Δ5 (MA29) and Δ6 (MA524) sequences were compared with each of the translated contigs using the FastA search (a Pearson and Lipman search for similarity between a query sequence and a group of sequences of the same type (nucleic acid or protein)). Homology among these sequences suggest the open reading frames of each contig. The homology among the M. alpina Δ5 and Δ6 to contigs 2535 and 3854933 were utilized to create the final contig called 253538a. Figure 13 is the FastA match of the final contig 253538a and MA29, and Figure 14 is the FastA match of the final contig

253538a and MA524. The DNA sequences for the various contigs are presented in SEQ ID NO:27 -SEQ ID NO:33 The various peptide sequences are shown in SEQ ID NO:34 - SEQ ID NO: 40.

Although the open reading frame was generated by merging the two contigs, the contig 2535 shows that there is a unique sequence in the beginning of this contig which does not match with the contig 3854933. Therefore, it is possible that these contigs were generated from independent desaturase like human genes.

The contig 253538a contains an open reading frame encoding 432 amino acids. It starts with Gin (CAG) and ends with the stop codon (TGA). The contig 253538a aligns with both M. alpina Δ5 and Δ6 sequences, suggesting that it could be either of the desaturases, as well as other known desaturases which share homology with each other. The individual contigs listed in Table 18, as well as the intermediate contig 2535 and the final contig 253538a can be utilized to isolate the complete genes for human desaturases. Uses of the human desaturases

These human sequences can be express in yeast and plants utilizing the procedures described in the preceding examples. For expression in mammalian cells transgenic animals, these genes may provide superior codon bias.

In addition, these sequences can be used to isolate related desaturase genes from other organisms.

Table 7

Example 14

Production of Oil in Microorganisms The sequences presented in the Sequence Listing including sequences that are homologous to these sequences as well as those sequences that are related to these sequences may be cloned into an appropriate vector as is well known in the art and as detailed in the previous examples. Such host cells can be utilized for the production of lipids and/or fats. Extraction of lipids or fats from host cells follows the general procedure described by Folch, et al., J.Biol. Chem. 226: 497 1957 which is hereby incorporated by reference. Host cells are grown under appropriate conditions and harvested. Harvested cells are homogenized mechanically with 20ml/g of a mixture of chloroform-methanol, 2:1 (v/v). In order to minimize oxidation, and anti-oxidant is added to the extraction solvent. If the oil is to be utilized for human consumption, vitamin E (α-tocopherol) is utilized as the anti-oxidant. After extraction, the solvent containing the lipid extract is washed with 0.2 volume of 0.58% NaCl. The mixture is thoroughly mixed and then transferred to a separating funnel. The mixed material is allowed to settle and two phases are separated out on standing. The bottom phase is collected and the solvent removed under vacuum. The residue contains the total tissue lipids. Yeast Strains Rich in Lipids

Under some circumstances, vectors will be transformed into yeast strains rich in lipids. In these strains, a high percentage of the cell lipids is often stored in fat droplets containing mostly the triglycerides. For these cells, simply breaking the cell wall by mechanical, pressure or enzymatic means will release the fat droplet. Once released, the fat is extracted with hexane for further processing.

Example 15 Further Processing of Oil Produced by Microorganisms

Further processing of oil produced by microorganisms is necessary to produce an edible food product. The refining process includes the following four steps.

1. De gumming: Degumming is utilized to remove phosphatides co-extracted with the oil which tend to separate from the oil as a sludge during storage. Two steps are utilized: (1) phosphatides are precipitated with water and then (2) with mild acid. The particles are removed by centrifugation.

2. Alkali Refining: This step is utilized to further reduce the phosphatide content and also the free fatty acids. In this step, the oil is first contacted with a small volume of concentrated phosphoric acid in a mixer to precipitate phosphatides. The acidified mixture is then contacted with an aqueous solution of sodium hydroxide to neutralize the free fatty acids as well as any excess phosphoric acid to form the soap phase. The soap is removed by centrifugation.

3. Adsorptive Bleaching: After alkali-refining, the crude oil still contains traces of soap and chlorophylloid compounds. The latter gives an undesirable green color to the oil. An acid-catalyzed clay or active carbon can be used to remove these compounds.

4. Deodorization: The final refining step of the edible oil process is deodorization. Deodorization is utilized to remove compounds from the oil that impart odor and taste typical of the host organism. The step involves steam distillation of the odor and flavor compounds and other volatile compounds such as free fatty acid from the oil. The oil is heated to 225-260°C under very low pressure to exclude air. Canola oil contains - and -tocopherol. However, deodorization can remove tocopherols to some extent. As the transgenic oil is more unsaturated than the regular canola oil, additional amount of antioxidant(s) may be supplemented to protect the oil from oxidation.

Example 16 Further Purification of Oil Produced by Microorganisms

Under certain circumstances, further purification and enriching of long- chain polyunsaturated fatty acids from transgenic microorganisms is needed. Such further processing steps include the following:

1. Fractionation: Oils are mixtures of triglycerides with different fatty acid compositions. Based on their different melting points, the triglycerides may be separated into different portions. Thermo-mechanical separation processes include distillation and crystallization. Distillation is commercially unsuitable, because the triglyceride mixtures have low vapor pressures and are unstable at high temperature. Crystallization (winterization) uses low temperature to separate solid triglyceride fraction from the liquid fraction. The liquid fraction is usually more unsaturated than the solid fraction. This method is a mild procedure especially suitable for triglyceride containing the polyunsaturated fatty acids. 2. Urea fractionation: Saturated fatty acids are more readily form stable complexes than do unsaturated fatty acids with urea. The procedure has been often used to enrich polyunsaturated fatty acids.

3. HPLC separation: HPLC using a reverse phase column can separate triglyceride molecules according to combined chain length of the fatty acid residues as well as the degree of unsaturation. Using this method, the highly unsaturated triglyceride molecules are eluted out the column first.

4. Supercritical fluid chromatography (SFC) or supercritical fluid extraction

(SFC): SFC is a method whereby a highly compressed gas above its critical temperature and critical pressure as a supercritical fluid is used to elute analytes from a chromatographic column. Triglycerides can be separated by SFC according to the combined chain length of the fatty acid residues using columns coated with relatively non -polar stationary phase, or according to the degree of unsaturation by using a more polar stationary phase. Generally, the triglyceride molecules can be separated firstly according to their carbon numbers and secondly according to unsaturation within each carbon number group. In order words, the most unsaturated molecules have the strongest retention to the stationary phase and are eluted out the column last.

Example 17

Manufacture of Transgenic Oil Nutritional Products

Once purified, transgenic oil is incorporated into various food products. The incorporation of transgenic oil into food products involves the following steps: (1) Preparation of slurry mix; (2) blending and (3) standardization:

I. Preparation of slurry mix:

Basically, three different slurries are prepared before the final blending. A. Protein-in-fat slurry (PIF)

Add the indicated amounts of oil blend (containing the transgenic canola oil and other oils at a designated ratio) to a kettle and heat at 120-140°F under moderate agitation. This is followed by the addition of DEK Premix, vitamin A, and soy lecithin, and Milei 75L WPC. Maintain the

PIF at 120-140°F under moderate agitation until use.

B. Carbohydrate/mineral slurry (CHO/MIN)

Heat the required amount of water to 140-160°F with high agitation. Add in order the indicated amounts of TM premix, Gum Arabic, and

Fibrim 300, respectively. Allow each addition to be completely dispersed under high agitation before the next ingredient is added.

Add in order the indicated amounts of different mineral salts, dry blend of Gellan Gum and sucrose, and fructooligosaccharides and maltrins.

Allow slurry to mix under high agitation until dispersed completely.

Maintain the CHO/MIN slurry at 140-160°F under moderate agitation until use.

C. Protein-in-water slurry (PIW)

Add the indicated amount of water to a kettle and heat to 140-160°F. Add the Alanates, mix under high agitation until protein is completely dispersed, then slow the agitation to moderate speed. Maintain PIW under moderate agitation at 130-150°F for at least half hour before blending. II. Blending:

Weigh the indicated amount of PIF slurry and add to the PIW slurry, and mix under moderate agitation for 5 min. Add the CHO/MIN to the blend, and adjust to the designated pH value with IN KOH. Thereafter, deaerate the mix by vacuum, heat the mixture to 160-180°F, and emulsify mix at 900-1100 psig in a homogenizer. The mix goes through the UHT treatment, homogenized and pass the mix through a holding tube, and then cool mix to 34-45°F and store until standardization.

III. Standardization:

Add indicated amount water, vitamin solution, flavor solution, and color solution to the batch. Allow to mix thoroughly. Transfer into can, sterilize and store until use.

Example 18

The PUFAs of the previous examples can be utilized in various nutritional supplements, infant formulations, nutritional substitutes and other nutrition solutions. In these formulations, transgenic oils are utilized.

I. INFANT FORMULATIONS A. Isomil® Soy Formula with Iron.

Usage: As a beverage for infants, children and adults with an allergy or sensitivity to cow's milk. A feeding for patients with disorders for which lactose should be avoided: lactase deficiency, lactose intolerance and galactosemia. Features:

• Soy protein isolate to avoid symptoms of cow's-milk-protein allergy or sensitivity

• Lactose-free formulation to avoid lactose-associated diarrhea • Low osmolaity (240 mOsm/kg water) to reduce risk of osmotic diarrhea.

• Dual carbohydrates (corn syrup and sucrose) designed to enhance carbohydrate absorption and reduce the risk of exceeding the absorptive capacity of the damaged gut.

• 1.8 mg of Iron (as ferrous sulfate) per 100 Calories to help prevent iron deficiency.

• Recommended levels of vitamins and minerals.

• Vegetable oils to provide recommended levels of essential fatty acids.

• Milk-white color, milk-like consistency and pleasant aroma.

Ingredients: (Pareve) 85% water, 4.9% corn syrup, 2.6% sugar (sucrose), 2.1% soy oil, 1.9% soy protein isolate, 1.4% coconut oil, 0.15% calcium citrate, 0.11 % calcium phosphate tribasic, potassium citrate, potassium phosphate monobasic, potassium chloride, mono- and disglycerides, soy lecithin, carrageenan, ascorbic acid, L-methionine, magnesium chloride, potassium phosphate dibasic, sodium chloride, choline chloride, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D₃ and cyanocobalamin_.

B. Isomil® DF Soy Formula For Diarrhea.

Usage: As a short-term feeding for the dietary management of diarrhea in infants and toddlers.

Features:

• First infant formula to contain added dietary fiber from soy fiber specifically for diarrhea management. • Clinically shown to reduce the duration of loose, watery stools during mild to severe diarrhea in infants.

• Nutritionally complete to meet the nutritional needs of the infant.

• Soy protein isolate with added L-methionine meets or exceeds an infant's requirement for all essential amino acids.

• Lactose-free formulation to avoid lactose-associated diarrhea.

• Low osmolality (240 mOsm/kg water) to reduce the risk of osmotic diarrhea.

• Meets or exceeds the vitamin and mineral levels recommended by the Committee on Nutrition of the American Academy of Pediatrics and required by the Infant Formula Act. • 1.8 mg of iron (as ferrous sulfate) per 100 Calories to help prevent iron deficiency.

• Vegetable oils to provide recommended levels of essential fatty acids.

Ingredients: (Pareve) 86% water, 4.8% corn syrup, 2.5% sugar (sucrose), 2.1% soy oil, 2.0% soy protein isolate, 1.4% coconut oil, 0.77% soy fiber, 0.12% calcium citrate, 0.11 % calcium phosphate tribasic, 0.10% potassium citrate, potassium chloride, potassium phosphate monobasic, mono- and disglycerides, soy lecithin, carrageenan, magnesium chloride, ascorbic acid, L-methionine, potassium phosphate dibasic, sodium chloride, choline chloride, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L- carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D₃ and cyanocobalamin C. Isomil® SF Sucrose-Free Soy Formula With Iron.

Usage: As a beverage for infants, children and adults with an allergy or sensitivity to cow's-milk protein or an intolerance to sucrose. A feeding for patients with disorders for which lactose and sucrose should be avoided. Features:

• Soy protein isolate to avoid symptoms of cow's-milk-protein allergy or sensitivity.

• Lactose-free formulation to avoid lactose-associated diarrhea (carbohydrate source is Polycose® Glucose Polymers). • Sucrose free for the patient who cannot tolerate sucrose.

• Low osmolality (180 mOsm/kg water) to reduce risk of osmotic diarrhea.

• 1.8 mg of iron (as ferrous sulfate) per 100 Calories to help prevent iron deficiency. • Recommended levels of vitamins and minerals.

• Vegetable oils to provide recommended levels of essential fatty acids.

• Milk-white color, milk-like consistency and pleasant aroma.

Ingredients: (Pareve) 75% water, 11.8% hydrolized cornstarch, 4.1% soy oil, 4.1% soy protein isolate, 2.8% coconut oil, 1.0% modified cornstarch,

0.38% calcium phosphate tribasic, 0.17% potassium citrate, 0.13% potassium chloride, mono- and disglycerides, soy lecithin, magnesium chloride, abscorbic acid, L-methionine, calcium carbonate, sodium chloride, choline chloride, carrageenan, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin

A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D₃ and cyanocobalamin. D. Isomil® 20 Soy Formula With Iron Ready To Feed, 20 Cal/fl oz.

Usage: When a soy feeding is desired.

Ingredients: (Pareve) 85% water, 4.9% corn syrup, 2.6% sugar (sucrose), 2.1% soy oil, 1.9% soy protein isolate, 1.4% coconut oil, 0.15% calcium citrate, 0.11% calcium phosphate tribasic, potassium citrate, potassium phosphate monobasic, potassium chloride, mono- and disglycerides, soy lecithin, carrageenan, abscorbic acid, L-methionine, magnesium chloride, potassium phosphate dibasic, sodium chloride, choline chloride, taurine, ferrous sulfate, m-inositol, alpha-tocopheryl acetate, zinc sulfate, L-carnitine, niacinamide, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, potassium iodide, phylloquinone, biotin, sodium selenite, vitamin D₃ and cyanocobalamin E. Similac® Infant Formula

Usage: When an infant formula is needed: if the decision is made to discontinue breastfeeding before age 1 year, if a supplement to breastfeeding is needed or as a routine feeding if breastfeeding is not adopted.

Features: • Protein of appropriate quality and quantity for good growth; heat-denatured, which reduces the risk of milk-associated enteric blood loss.

• Fat from a blend of vegetable oils (doubly homogenized), providing essential linoleic acid that is easily absorbed. • Carbohydrate as lactose in proportion similar to that of human milk.

• Low renal solute load to minimize stress on developing organs.

• Powder, Concentrated Liquid and Ready To Feed forms. Ingredients: Water, nonfat milk, lactose, soy oil, coconut oil, mono- and diglycerides, soy lecithin, abscorbic acid, carrageenan, choline chloride, taurine, m-inositol, alpha-tocopheryl acetate, zinc sulfate, niacinamid, ferrous sulfate, calcium pantothenate, cupric sulfate, vitamin A palmitate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, phylloquinone, biotin, sodium selenite, vitamin D₃ and cyanocobalamin.

F. Similac® NeoCare Premature Infant Formula With Iron

Usage: For premature infants' special nutritional needs after hospital discharge. Similac NeoCare is a nutritionally complete formula developed to provide premature infants with extra calories, protein, vitamins and minerals needed to promote catch-up growth and support development.

Features:

• Reduces the need for caloric and vitamin supplementation. More calories (22 Cal/fl oz) then standard term formulas (20 Cal/fl oz). • Highly absorbed fat blend, with medium-chain triglycerides

(MCT oil) to help meet the special digestive needs of premature infants.

• Higher levels of protein, vitamins and minerals per 100 Calories to extend the nutritional support initiated in-hospital.

• More calcium and phosphorus for improved bone mineralization. Ingredients: Corn syrup solids, nonfat milk, lactose, whey protein concentrate, soy oil, high-oleic safflower oil, fractionated coconut oil (medium- chain triglycerides), coconut oil, potassium citrate, calcium phosphate tribasic, calcium carbonate, ascorbic acid, magnesium chloride, potassium chloride, sodium chloride, taurine, ferrous sulfate, m-inositol, choline chloride, ascorbyl palmitate, L-carnitine, alpha-tocopheryl acetate, zinc sulfate, niacinamide, mixed tocopherols, sodium citrate, calcium pantothenate, cupric sulfate, thiamine chloride hydrochloride, vitamin A palmitate, beta carotene, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulfate, phylloquinone, biotin, sodium selenite, vitamin D₃ and cyanocobalamin. G. Similac Natural Care Low-Iron Human Milk Fortifier Ready To Use, 24 Cal/fl oz.

Usage: Designed to be mixed with human milk or to be fed alternatively with human milk to low-birth-weight infants. Ingredients: Water, nonfat milk, hydrolyzed cornstarch, lactose, fractionated coconut oil (medium-chain triglycerides), whey protein concentrate, soil oil, coconut oil, calcium phosphate tribasic, potassium citrate, magnesium chloride, sodium citrate, ascorbic acid, calcium carbonate, mono- and diglycerides, soy lecithin, carrageenan, choline chloride, m-inositol, taurine, niacinamide, L-carnitine, alpha tocopheryl acetate, zinc sulfate, potassium chloride, calcium pantothenate, ferrous sulfate, cupric sulfate, riboflavin, vitamin A palmitate, thiamine chloride hydrochloride, pyridoxine hydrochloride, biotin, folic acid, manganese sulfate, phylloquinone, vitamin D₃, sodium selenite and cyanocobalamin. Various PUFAs of this invention can be substituted and/or added to the infant formulae described above and to other infant formulae known to those in the art..

II. NUTRITIONAL FORMULATIONS

A. ENSURE® Usage: ENSURE is a low-residue liquid food designed primarily as an oral nutritional supplement to be used with or between meals or, in appropriate amounts, as a meal replacement. ENSURE is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets. Although it is primarily an oral supplement, it can be fed by tube. Patient Conditions:

• For patients on modified diets

• For elderly patients at nutrition risk

• For patients with involuntary weight loss

• For patients recovering from illness or surgery • For patients who need a low-residue diet

Ingredients:

Water, Sugar (Sucrose), Maltodextrin (Corn), Calcium and Sodium Caseinates, High-Oleic Safflower Oil, Soy Protein Isolate, Soy Oil, Canola Oil, Potassium Citrate, Calcium Phosphate Tribasic, Sodium Citrate, Magnesium

Chloride, Magnesium Phosphate Dibasic, Artificial Flavor, Sodium Chloride, Soy Lecithin, Choline Chloride, Ascorbic Acid, Carrageenan, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Gellan Gum, Niacinamide, Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate, Vitamin A Palmitate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride,

Riboflavin, Folic Acid, Sodium Molybdate, Chromium Chloride, Biotin, Potassium Iodide, Sodium Selenate.

B. ENSURE® BARS Usage: ENSURE BARS are complete, balanced nutrition for supplemental use between or with meals. They provide a delicious, nutrient- rich alternative to other snacks. ENSURE BARS contain <1 g lactose/bar, and Chocolate Fudge Brownie flavor is gluten-free. (Honey Graham Crunch flavor contains gluten.) Patient Conditions:

• For patients who need extra calories, protein, vitamins and minerals

• Especially useful for people who do not take in enough calories and nutrients

• For people who have the ability to chew and swallow • Not to be used by anyone with a peanut allergy or any type of allergy to nuts.

Ingredients:

Honey Graham Crunch — High-Fructose Corn Syrup, Soy Protein Isolate, Brown Sugar, Honey, Maltodextrin (Corn), Crisp Rice (Milled Rice, Sugar [Sucrose], Salt [Sodium Chloride] and Malt), Oat Bran, Partially Hydrogenated Cottonseed and Soy Oils, Soy Polysaccharide, Glycerine, Whey Protein Concentrate, Polydextrose, Fructose, Calcium Caseinate, Cocoa Powder, Artificial Flafors, Canola Oil, High-Oleic Safflower Oil, Nonfat Dry Milk, Whey Powder, Soy Lecithin and Corn Oil. Manufactured in a facility that processes nuts.

Vitamins and Minerals:

Calcium Phosphate Tribasic, Potassium Phosphate Dibasic, Magnesium Oxide, Salt (Sodium Chloride), Potassium Chloride, Ascorbic Acid, Ferric Orthophosphate, Alpha-Tocopheryl Acetate, Niacinamide, Zinc Oxide, Calcium

Pantothenate, Copper Gluconate, Manganese Sulfate, Riboflavin, Beta- Carotene, Pyridoxine Hydrochloride, Thiamine Mononitrate, Folic Acid, Biotin, Chromium Chloride, Potassium Iodide, Sodium Selenate, Sodium Molybdate, Phylloquinone, Vitamin D₃ and Cyanocobalamin. Protein:

Honey Graham Crunch - The protein source is a blend of soy protein isolate and milk proteins.

Soy protein isolate 74%

Milk proteins 26% Fat:

Honey Graham Crunch - The fat source is a blend of partially hydrogenated cottonseed and soybean, canola, high oleic safflower, and corn oils, and soy lecithin.

Partially hydrogenated cottonseed and soybean oil 76% Canola oil 8%

High-oleic safflower oil 8%

Com oil 4%

Soy lecithin 4% Carbohydrate:

Honey Graham Crunch - The carbohydrate source is a combination of high-fructose corn syrup, brown sugar, maltodextrin, honey, crisp rice, glycerine, soy polysaccharide, and oat bran. High-fructose com syrup 24%

Brown sugar 21%

Maltodextrin 12%

Honey 11%

Crisp rice 9% Glycerine 9%

Soy polysaccharide 7%

Oat bran 7%

C. ENSURE® HIGH PROTEIN Usage: ENSURE HIGH PROTEIN is a concentrated, high-protein liquid food designed for people who require additional calories, protein, vitamins, and minerals in their diets. It can be used as an oral nutritional supplement with or between meals or, in appropriate amounts, as a meal replacement. ENSURE HIGH PROTEIN is lactose- and gluten-free, and is suitable for use by people recovering from general surgery or hip fractures and by patients at risk for pressure ulcers.

Patient Conditions

• For patients who require additional calories, protein, vitamins, and minerals, such as patients recovering from general surgery or hip fractures, patients at risk for pressure ulcers, and patients on low-cholesterol diets

Features-

• Low in saturated fat

• Contains 6 g of total fat and < 5 mg of cholesterol per serving

• Rich, creamy taste • Excellent source of protein, calcium, and other essential vitamins and minerals

• For low-cholesterol diets

• Lactose-free, easily digested Ingredients:

Vanilla Supreme: Water, Sugar (Sucrose), Maltodextrin (Com), Calcium and Sodium Caseinates, High-Oleic Safflower Oil, Soy Protein Isolate, Soy Oil, Canola Oil, Potassium Citrate, Calcium Phosphate Tribasic, Sodium Citrate, Magnesium Chloride, Magnesium Phosphate Dibasic, Artificial Flavor, Sodium Chloride, Soy Lecithin, Choline Chloride, Ascorbic Acid, Carrageenan, Zinc

Sulfate, Ferrous Suffate, Alpha-Tocopheryl Acetate, Gellan Gum, Niacinamide, Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate, Vitamin A Palmitate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Folio Acid, Sodium Motybdate, Chromium Chloride, Biotin, Potassium Iodide, Sodium Selenate, Phylloquinone, Vitamin D.3 and

Cyanocobalamin.

Protein:

The protein source is a blend of two high-biologic-value proteins: casein and soy. Sodium and calcium caseinates 85%

Soy protein isolate 15%

Fat:

The fat source is a blend of three oils: high-oleic safflower, canola, and soy.

High-oleic safflower oil 40% Canola oil 30%

Soy oil 30%

The level of fat in ENSURE HIGH PROTEIN meets American Heart Association (AHA) guidelines. The 6 grams of fat in ENSURE HIGH PROTEIN represent 24% of the total calories, with 2.6% of the fat being from saturated fatty acids and 7.9% from polyunsaturated fatty acids. These values are within the AHA guidelines of < 30% of total calories from fat, < 1 0% of the calories from saturated fatty acids, and < 1 0% of total calories from polyunsaturated fatty acids.

Carbohydrate:

ENSURE HIGH PROTEIN contains a combination of maltodextrin and sucrose. The mild sweetness and flavor variety (vanilla supreme, chocolate royal, wild berry, and banana), plus VARI-FLAVORSO® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

Vanilla and other nonchocolate flavors

Sucrose 60%

Maltodextrin 40% Chocolate

Sucrose 70%

Maltodextrin 30%

D. ENSURE ® LIGHT Usage: ENSURE LIGHT is a low-fat liquid food designed for use as an oral nutritional supplement with or between meals. ENSURE LIGHT is lactose- and gluten-free, and is suitable for use in modified diets, including low- cholesterol diets.

Patient Conditions: • For normal-weight or overweight patients who need extra nutrition in a supplement that contains 50% less fat and 20% fewer calories than ENSURE

• For healthy adults who don't eat right and need extra nutrition Features:

• Low in fat and saturated fat

• Contains 3 g of total fat per serving and < 5 mg cholesterol

• Rich, creamy taste • Excellent source of calcium and other essential vitamins and minerals

• For low-cholesterol diets

• Lactose-free, easily digested

Ingredients:

French Vanilla: Water, Maltodextrin (Corn), Sugar (Sucrose), Calcium Caseinate, High-Oleic Safflower Oil, Canola Oil, Magnesium Chloride, Sodium

Citrate, Potassium Citrate, Potassium Phosphate Dibasic, Magnesium Phosphate Dibasic, Natural and Artificial Flavor, Calcium Phosphate Tribasic, Cellulose Gel, Choline Chloride, Soy Lecithin, Carrageenan, Salt (Sodium Chloride), Ascorbic Acid, Cellulose Gum, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Zinc Sulfate, Niacinamide, Manganese Sulfate, Calcium Pantothenate, Cupric

Sulfate, Thiamine Chloride Hydrochloride, Vitamin A Palmitate, Pyridoxine Hydrochloride, Riboflavin, Chromium Chloride, Folic Acid, Sodium Molybdate, Biotin, Potassium Iodide, Sodium Selenate, Phylloquinone, Vitamin D₃ and Cyanocobalamin. Protein:

The protein source is calcium caseinate.

Calcium caseinate 100%

Fat

The fat source is a blend of two oils: high-oleic safflower and canola. High-oleic safflower oil 70%

Canola oil 30%

The level of fat in ENSURE LIGHT meets American Heart Association (AHA) guidelines. The 3 grams of fat in ENSURE LIGHT represent 13.5% of the total calories, with 1.4% of the fat being from saturated fatty acids and 2.6% from polyunsaturated fatty acids. These values are within the AHA guidelines of < 30% of total calories from fat, < 1 0% of the calories from saturated fatty acids, and < 1 0% of total calories from polyunsaturated fatty acids. Carbohydrate

ENSURE LIGHT contains a combination of maltodextrin and sucrose. The chocolate flavor contains corn syrup as well. The mild sweetness and flavor variety (French vanilla, chocolate supreme, strawberry swirl), plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

Vanilla and other nonchocolate flavors

Sucrose 51%

Maltodextrin 49%

Chocolate Sucrose 47.0%

Corn Syrup 26.5%

Maltodextrin 26.5%

Vitamins and Minerals

An 8-fl-oz serving of ENSURE LIGHT provides at least 25% of the RDIs for 24 key vitamins and minerals.

Caffeine

Chocolate flavor contains 2.1 mg caffeine/8 fl oz.

E. ENSURE PLUS® Usage: ENSURE PLUS is a high-calorie, low-residue liquid food for use when extra calories and nutrients, but a normal concentration of protein, are needed. It is designed primarily as an oral nutritional supplement to be used with or between meals or, in appropriate amounts, as a meal replacement. ENSURE PLUS is lactose- and gluten-free. Although it is primarily an oral nutritional supplement, it can be fed by tube.

Patient Conditions:

• For patients who require extra calories and nutrients, but a normal concentration of protein, in a limited volume

• For patients who need to gain or maintain healthy weight Features

• Rich, creamy taste

• Good source of essential vitamins and minerals Ingredients

Vanilla: Water, Corn Syrup, Maltodextrin (Corn), Com Oil, Sodium and Calcium Caseinates, Sugar (Sucrose), Soy Protein Isolate, Magnesium Chloride, Potassium Citrate, Calcium Phosphate Tribasic, Soy Lecithin, Natural and Artificial Flavor, Sodium Citrate, Potassium Chloride, Choline Chloride, Ascorbic Acid, Carrageenan, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl

Acetate, Niacinamide, Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Vitamin A Palmitate, Folic Acid, Biotin, Chromium Chloride, Sodium Molybdate, Potassium Iodide, Sodium Selenite, Phylloquinone, Cyanocobalamin and Vitamin D₃.

Protein

The protein source is a blend of two high-biologic-value proteins: casein and soy.

Sodium and calcium caseinates 84% Soy protein isolate 16%

Fat

The fat source is com oil.

Corn oil 100% Carbohydrate

ENSURE PLUS contains a combination of maltodextrin and sucrose. The mild sweetness and flavor variety (vanilla, chocolate, strawberry, coffee, buffer pecan, and eggnog), plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

Vanilla, strawberry, butter pecan, and coffee flavors

Com Syrup 39%

Maltodextrin 38% Sucrose 23%

Chocolate and eggnog flavors

Corn Syrup 36%

Maltodextrin 34%

Sucrose 30% Vitamins and Minerals

An 8-fl-oz serving of ENSURE PLUS provides at least 15% of the RDIs for 25 key Vitamins and minerals.

Caffeine

Chocolate flavor contains 3.1 mg Caffeine/8 fl oz. Coffee flavor contains a trace amount of caffeine.

F. ENSURE PLUS® HN

Usage: ENSURE PLUS HN is a nutritionally complete high-calorie, high-nitrogen liquid food designed for people with higher calorie and protein needs or limited volume tolerance. It may be used for oral supplementation or for total nutritional support by tube. ENSURE PLUS HN is lactose- and gluten- free. Patient Conditions:

• For patients with increased calorie and protein needs, such as following surgery or injury

• For patients with limited volume tolerance and early satiety Features

• For supplemental or total nutrition

• For oral or tube feeding

• 1.5 CaVmL

• High nitrogen • Calorically dense

Ingredients

Vanilla: Water, Maltodextrin (Com), Sodium and Calcium Caseinates, Co Oil, Sugar (Sucrose), Soy Protein Isolate, Magnesium Chloride, Potassium Citrate, Calcium Phosphate Tribasic, Soy Lecithin, Natural and Artificial Flavor, Sodium Citrate, Choline Chloride, Ascorbic Acid, Taurine, L-Carnitine,

Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Niacinamide, Carrageenan, Calcium Pantothenate, Manganese Sulfate, Cupric Sulfate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Vitamin A Palmitate, Folic Acid, Biotin, Chromium Chloride, Sodium Molybdate, Potassium Iodide, Sodium Selenite, Phylloquinone,

Cyanocobalamin and Vitamin D₃.

G. ENSURE® POWDER

Usage: ENSURE POWDER (reconstituted with water) is a low-residue liquid food designed primarily as an oral nutritional supplement to be used with or between meals. ENSURE POWDER is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets. Patient Conditions:

• For patients on modified diets

• For elderly patients at nutrition risk

• For patients recovering from illness/surgery • For patients who need a low-residue diet

Features

• Convenient, easy to mix

• Low in saturated fat

• Contains 9 g of total fat and < 5 mg of cholesterol per serving • High in vitamins and minerals

• For low-cholesterol diets

• Lactose-free, easily digested

Ingredients: Com Syrup, Maltodextrin (Com), Sugar (Sucrose), Com Oil, Sodium and Calcium Caseinates, Soy Protein Isolate, Artificial Flavor, Potassium Citrate, Magnesium Chloride, Sodium Citrate, Calcium Phosphate

Tribasic, Potassium Chloride, Soy Lecithin, Ascorbic Acid, Choline Chloride, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Niacinamide, Calcium Pantothenate, Manganese Sulfate, Thiamine Chloride Hydrochloride, Cupric Sulfate, Pyridoxine Hydrochloride, Riboflavin, Vitamin A Palmitate, Folic Acid, Biotin, Sodium Molybdate, Chromium Chloride, Potassium Iodide,

Sodium Selenate, Phylloquinone, Vitamin D₃ and Cyanocobalamin.

Protein

The protein source is a blend of two high-biologic-value proteins: casein and soy. Sodium and calcium caseinates 84%

Soy protein isolate 16% 00/20602 _ιoi_ PCT/US99/22686

Fat

The fat source is co oil.

Com oil 100%

Carbohydrate ENSURE POWDER contains a combination of com syrup, maltodextrin, and sucrose. The mild sweetness of ENSURE POWDER, plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, helps to prevent flavor fatigue and aid in patient compliance.

Vanilla Com Syrup 35%

Maltodextrin 35%

Sucrose 30%

H. ENSURE® PUDDING Usage: ENSURE PUDDING is a nutrient-dense supplement providing balanced nutrition in a nonliquid form to be used with or between meals. It is appropriate for consistency-modified diets (e.g., soft, pureed, or full liquid) or for people with swallowing impairments. ENSURE PUDDING is gluten-free.

Patient Conditions: • For patients on consistency-modified diets (e.g., soft, pureed, or full liquid)

• For patients with swallowing impairments Features

• Rich and creamy, good taste

• Good source of essential vitamins and minerals • Convenient-needs no refrigeration

• Gluten-free Nutrient Profile per 5 oz: Calories 250, Protein 10.9%, Total Fat 34.9%, Carbohydrate 54.2%

Ingredients:

Vanilla: Nonfat Milk, Water, Sugar (Sucrose), Partially Hydrogenated Soybean Oil, Modified Food Starch, Magnesium Sulfate. Sodium Stearoyl

Lactylate, Sodium Phosphate Dibasic, Artificial Flavor, Ascorbic Acid, Zinc Sulfate, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Choline Chloride, Niacinamide, Manganese Sulfate, Calcium Pantothenate, FD&C Yellow #5, Potassium Citrate, Cupric Sulfate, Vitamin A Palmitate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, FD&C Yellow #6, Folic

Acid, Biotin, Phylloquinone, Vitamin D3 and Cyanocobalamin.

Protein

The protein source is nonfat milk.

Nonfat milk 100% Fat

The fat source is hydrogenated soybean oil.

Hydrogenated soybean oil 100%

Carbohydrate

ENSURE PUDDING contains a combination of sucrose and modified food starch. The mild sweetness and flavor variety (vanilla, chocolate, butterscotch, and tapioca) help prevent flavor fatigue. The product contains 9.2 grams of lactose per serving.

Vanilla and other nonchocolate flavors

Sucrose 56% Lactose 27%

Modified food starch 17% Chocolate

Sucrose. 58% Lactose 26%

Modified food starch 16%

I. ENSURE® WITH FIBER Usage: ENSURE WITH FIBER is a fiber-containing, nutritionally complete liquid food designed for people who can benefit from increased dietary fiber and nutrients. ENSURE WITH FIBER is suitable for people who do not require a low-residue diet. It can be fed orally or by tube, and can be used as a nutritional supplement to a regular diet or, in appropriate amounts, as a meal replacement. ENSURE WITH FIBER is lactose- and gluten-free, and is suitable for use in modified diets, including low-cholesterol diets.

Patient Conditions

• For patients who can benefit from increased dietary fiber and nutrients Features • New advanced formula-low in saturated fat, higher in vitamins and minerals

• Contains 6 g of total fat and < 5 mg of cholesterol per serving

• Rich, creamy taste

• Good source of fiber

• Excellent source of essential vitamins and minerals • For low-cholesterol diets

• Lactose- and gluten-free

Ingredients

Vanilla: Water, Maltodextrin (Com), Sugar (Sucrose), Sodium and Calcium Caseinates, Oat Fiber, High-Oleic Safflower Oil, Canola Oil, Soy Protein Isolate, Co Oil, Soy Fiber, Calcium Phosphate Tribasic, Magnesium Chloride,

Potassium Citrate, Cellulose Gel, Soy Lecithin, Potassium Phosphate Dibasic, Sodium Citrate, Natural and Artificial Flavors, Choline Chloride, Magnesium Phosphate, Ascorbic Acid, Cellulose Gum, Potassium Chloride, Carrageenan, Ferrous Sulfate, Alpha-Tocopheryl Acetate, Zinc Sulfate, Niacinamide, Manganese Sulfate, Calcium Pantothenate, Cupric Sulfate, Vitamin A Palmitate, Thiamine Chloride Hydrochloride, Pyridoxine Hydrochloride, Riboflavin, Folic Acid, Chromium Chloride, Biotin, Sodium Molybdate,

Potassium Iodide, Sodium Selenate, Phylloquinone, Vitamin D₃ and Cyanocobalamin.

Protein

The protein source is a blend of two high-biologic -value proteins- casein and soy.

Sodium and calcium caseinates 80%

Soy protein isolate 20%

Fat

The fat source is a blend of three oils: high-oleic safflower, canola, and com.

High-oleic safflower oil 40%

Canola oil 40%

Com oil 20%

The level of fat in ENSURE WITH FIBER meets American Heart Association (AHA) guidelines. The 6 grams of fat in ENSURE WITH FIBER represent 22% of the total calories, with 2.01 % of the fat being from saturated fatty acids and 6.7% from polyunsaturated fatty acids. These values are within the AHA guidelines of < 30% of total calories from fat, < 1 0% of the calories from saturated fatty acids, and < 1 0% of total calories from polyunsaturated fatty acids.

Carbohydrate

ENSURE WITH FIBER contains a combination of maltodextrin and sucrose. The mild sweetness and flavor variety (vanilla, chocolate, and butter pecan), plus VARI-FLAVORS® Flavor Pacs in pecan, cherry, strawberry, lemon, and orange, help to prevent flavor fatigue and aid in patient compliance.

Vanilla and other nonchocolate flavors

Maltodextrin 66% Sucrose 25%

Oat Fiber 7%

Soy Fiber 2% Chocolate

Maltodextrin 55% Sucrose 36%

Oat Fiber 7%

Soy Fiber 2%

Fiber

The fiber blend used in ENSURE WITH FIBER consists of oat fiber and soy polysaccharide. This blend results in approximately 4 grams of total dietary fiber per 8-fl-oz can. The ratio of insoluble to soluble fiber is 95:5.

The various nutritional supplements described above and known to others of skill in the art can be substituted and/or supplemented with the PUFAs of this invention. J. Oxepa™ Nutritional Product

Oxepa is low-carbohydrate, calorically dense enteral nutritional product designed for the dietary management of patients with or at risk for ARDS. It has a unique combination of ingredients, including a patented oil blend containing eicosapentaenoic acid (EPA from fish oil), γ-linolenic acid (GLA from borage oil), and elevated antioxidant levels. Caloric Distribution:

• Caloric density is high at 1.5 Cal/mL (355 Cal/8 fl oz), to minimize the volume required to meet energy needs.

• The distribution of Calories in Oxepa is shown in Table 8.

Fat:

• Oxepa contains 22.2 g of fat per 8-fl oz serving (93.7 g/L).

• The fat source is a oil blend of 31.8% canola oil, 25% medium-chain triglycerides (MCTs), 20% borage oil, 20% fish oil, and 3.2 % soy lecithin. The typical fatty acid profile of Oxepa is shown in Table 9.

• Oxepa provides a balanced amount of polyunsaturated, monounsaturated, and saturated fatty acids, as shown in Table 10.

• Medium-chain trigylcerides (MCTs) — 25% of the fat blend ~ aid gastric emptying because they are absorbed by the intestinal tract without emulsification by bile acids.

The various fatty acid components of Oxepa™ nutritional product can be substituted and/or supplemented with the PUFAs of this invention.

Carbohydrate:

• The carbohydrate content is 25.0 g per 8-fl-oz serving (105.5 g/L).

• The carbohydrate sources are 45% maltodextrin (a complex carbohydrate) and 55% sucrose (a simple sugar), both of which are readily digested and absorbed.

• The high-fat and low-carbohydrate content of Oxepa is designed to minimize carbon dioxide (CO₂) production. High CO₂ levels can complicate weaning in ventilator-dependent patients. The low level of carbohydrate also may be useful for those patients who have developed stress-induced hyperglycemia.

• Oxepa is lactose-free. Dietary carbohydrate, the amino acids from protein, and the glycerol moiety of fats can be converted to glucose within the body. Throughout this process, the carbohydrate requirements of glucose-dependent tissues (such as the central nervous system and red blood cells) are met. However, a diet free of carbohydrates can lead to ketosis, excessive catabolism of tissue protein, and loss of fluid and electrolytes. These effects can be prevented by daily ingestion of 50 to 100 g of digestible carbohydrate, if caloric intake is adequate. The carbohydrate level in Oxepa is also sufficient to minimize gluconeogenesis, if energy needs are being met.

Protein: • Oxepa contains 14.8 g of protein per 8-fl-oz serving (62.5 g/L).

• The total calorie/nitrogen ratio ( 150: 1 ) meets the need of stressed patients.

• Oxepa provides enough protein to promote anabolism and the maintenance of lean body mass without precipitating respiratory problems. High protein intakes are a concern in patients with respiratory insufficiency. Although protein has little effect on CO₂ production, a high protein diet will increase ventilatory drive.

• The protein sources of Oxepa are 86.8% sodium caseinate and 13.2% calcium caseinate.

• As demonstrated in Table 11, the amino acid profile of the protein system in Oxepa meets or surpasses the standard for high quality protein set by the

National Academy of Sciences.

• Oxepa is gluten-free. All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

Claims

1. A transgenic insect cell comprising: a nucleotide sequence which encodes a polypeptide wherein the sequence of the polypeptide comprises a sequence selected from the group consisting of residues 50-53, 39-43, 172-176, 204-213 and 390-402 of SEQ ID NO:2.

2. An oil or fraction thereof isolated from the cell of claim 1

3. A fatty acid isolated from the cell of claim 1.

4. A method of treating or preventing malnutrition comprising administering said oil of claim 2 to a patient in need of said treatment or prevention in an amount sufficient to effect said treatment or prevention.

5. A pharmaceutical composition comprising said oil or fraction of claim 2 and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 5, wherein said pharmaceutical composition is in the form of a solid or a liquid.

7. The pharmaceutical composition of claim 6, wherein said pharmaceutical composition is in a capsule or tablet form.

8. The pharmaceutical composition of claim 5 further comprising at least one nutrient selected from the group consisting of a vitamin, a mineral, a carbohydrate, a sugar, an amino acid, a free fatty acid, a phospholipid, an antioxidant, and a phenolic compound.

9. A nutritional formula comprising said oil or fraction thereof of claim 3.

10. The nutritional formula of claim 9, wherein said nutritional formula is selected from the group consisting of an infant formula, a dietary supplement, and a dietary substitute.

11. The nutritional formula of claim 10, wherein said infant formula, dietary supplement or dietary supplement is in the form of a liquid or a solid.

12. An infant formula comprising said microbial oil or fraction thereof of claim 2.

13. The infant formula of claim 12 further comprising at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, mono- and diglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, and other protein hydrolysates.

14. The infant formula of claim 12 further comprising at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex; and at least one mineral selected from the group consisting of calcium, magnesium, zinc, manganese, sodium, potassium, phosphorus, copper, chloride, iodine, selenium, and iron.

15. A dietary supplement comprising said microbial oil or fraction thereof of claim 2.

16. The dietary supplement of claim 15 further comprising at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, mono- and diglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, and other protein hydrolysates.

17. The dietary supplement of claim 16 further comprising at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex; and at least one mineral selected from the group consisting of calcium, magnesium, zinc, manganese, sodium, potassium, phosphorus, copper, chloride, iodine, selenium, and iron.

18. The dietary supplement of claim 15 wherein said dietary supplement is administered to a human or an animal.

19. A dietary substitute comprising said oil or fraction thereof of claim 2.

20. The dietary substitute of claim 19 further comprising at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, mono- and diglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, and other protein hydrolysates.

21. The dietary substitute of claim 20 further comprising at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex; and at least one mineral selected from the group consisting of calcium, magnesium, zinc, manganese, sodium, potassium, phosphorus, copper, chloride, iodine, selenium, and iron.

22. The dietary substitute of claim 19 wherein said dietary substitute is administered to a human or animal.

23. A method of treating a patient having a condition caused by insufficient intake or production of polyunsaturated fatty acids comprising administering to said patient said dietary supplement of claim 15 in an amount sufficient to effect said treatment.

24. The method of claim 23, wherein said dietary supplement is administered enterally or parenterally.

25. A cosmetic comprising said oil or fraction thereof of claim 2.

26. The cosmetic of claim 24, wherein said cosmetic is applied topically.

27. The pharmaceutical composition of claim 5, wherein said pharmaceutical composition is administered to a human or an animal.

28. An animal feed comprising said oil or fraction thereof of claim 2.

29. The insect cell of claim 3 wherein said fatty acid is gamma- linolenic acid.

30. A transgenic insect cell comprising a nucleotide sequence which encodes a polypeptide wherein the sequence of the polypeptide comprises the sequence depicted in SEQ ID NO:4.

31. An oil or fraction thereof isolated from the insect cell of claim 30.

32. A method of treating or preventing malnutrition comprising administering said oil of claim 31 to a patient in need of said treatment or prevention in an amount sufficient to effect said treatment or prevention.

33. A pharmaceutical composition comprising said oil or fraction of claim 31 and a pharmaceutically acceptable carrier.

34. The pharmaceutical composition of claim 33, wherein said pharmaceutical composition is in the form of a solid or a liquid.

35. The pharmaceutical composition of claim 33, wherein said pharmaceutical composition is in a capsule or tablet form.

36. The pharmaceutical composition of claim 33 further comprising at least one nutrient selected from the group consisting of a vitamin, a mineral, a carbohydrate, a sugar, an amino acid, a free fatty acid, a phospholipid, an antioxidant, and a phenolic compound.

37. A nutritional formula comprising said oil or fraction thereof of claim 31.

38. The nutritional formula of claim 37, wherein said nutritional formula is selected from the group consisting of an infant formula, a dietary supplement, and a dietary substitute.

39. The nutritional formula of claim 30, wherein said infant formula, dietary supplement or dietary supplement is in the form of a liquid or a solid.

40. An infant formula comprising said oil or fraction thereof of claim

31.

41. The infant formula of claim 40 further comprising at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, mono- and diglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, and other protein hydrolysates.

42. The infant formula of claim 41 further comprising at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex; and at least one mineral selected from the group consisting of calcium, magnesium, zinc, manganese, sodium, potassium, phosphorus, copper, chloride, iodine, selenium, and iron.

43. A dietary supplement comprising said oil or fraction thereof of claim 31.

44. The dietary supplement of claim 43 further comprising at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, mono- and diglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, and other protein hydrolysates.

45. The dietary supplement of claim 44 further comprising at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex; and at least one mineral selected from the group consisting of calcium, magnesium, zinc, manganese, sodium, potassium, phosphorus, copper, chloride, iodine, selenium, and iron.

46. The dietary supplement of claim 45 wherein said dietary supplement is administered to a human or an animal.

47. A dietary substitute comprising said microbial oil or fraction thereof of claim 31.

48. The dietary substitute of claim 47 further comprising at least one macronutrient selected from the group consisting of coconut oil, soy oil, canola oil, mono- and diglycerides, glucose, edible lactose, electrodialysed whey, electrodialysed skim milk, milk whey, soy protein, and other protein hydrolysates.

49. The dietary substitute of claim 48 further comprising at least one vitamin selected from the group consisting of Vitamins A, C, D, E, and B complex; and at least one mineral selected from the group consisting of calcium, magnesium, zinc, manganese, sodium, potassium, phosphoms, copper, chloride, iodine, selenium, and iron.

50. A cosmetic comprising said oil or fraction thereof of claim 31.

51. An animal feed comprising said oil or fraction thereof of claim 31.

52. A method for producing an oil or fraction thereof comprising growing one or more transgenic insect cells under suitable conditions whereby said cells express a transgenic polypeptide wherein the sequence of said polypeptide comprises a sequence selected from the group of polypeptides consisting of SEQ ID NO:4 or residues 50-53, 39-443, 172-176, 204-213 and 390-402 of SEQ ID NO:2.

53. The method according to claim 52 including the step of extracting said insect cells with an organic solvent.

54. The method according to claim 52 wherein said oil includes phosphatides and said phosphatides are removed by precipitation with water and with mild acid.

55. The method according to claim 53 wherein said oil is treated with phosphosphoric acid to precipitate said phosphatides.

56. The method of claim 54 wherein said phosphoric acid is neutralized with sodium hydroxide.

57. The method of claim 54 wherein said oil is treated with acid catalyzed clay or activated carbon.

58. The method of claim 54 including the further step of deodorizing said oil by subjecting said oil to steam distillation.

59. A method for producing a desaturase polypeptide comprising growing one or more transgenic insect cells under suitable conditions whereby said cells express a transgenic polypeptide wherein the sequence of said polypeptide comprises a sequence selected from a group of polypeptides consisting of SEQ ID NO:4 or residues 50-53, 39-443, 172-176, 204-213 and 390-402 of SEQ ID NO:2.

60. Isolated and purified desaturase protein purified by the method of claim 59.

61. Antibodies directed to the protein of claim 60.

62. The antibodies of claim 61 wherein said antibodies are polyclonal antibodies.

63. The antibodies of claim 61 wherein said antibodies are monoclonal antibodies.

64. A method for production of stearidonic acid in an insect cell culture, said method comprising: growing an insect cell culture having a plurality of recombinant insect cells, wherein said insect cells or an ancestor of said insect cells were transformed with a vector comprising fungal DNA encoding a Δ6 desaturase polypeptide which converts γ-linolenic acid to stearidonic acid, wherein said DNA is operably associated with an expression control sequence functional in said yeast cells, under conditions whereby said DNA is expressed, whereby stearidonic acid is produced from γ-linolenic acid in said insect cell culture.

65. The method according to claim 64 wherein said fungal DNA is

Mortierella DNA.

66. The method according to claim 65 wherein Mortierella is one of the species Mortierella alpina.

67. The method according to claim 64, wherein said γ-linolenic acid is exogenously supplied.

68. The method according to claim 64 wherein said conditions are inducible.

69. The method according to claim 64 wherein said fungal DNA comprises the DNA sequence depicted in SEQ ID NO: 1.

70. The method according to claim 64 wherein the polypeptide comprises the polypeptide sequence depicted in SEQ ID NO:2.

71. A method for production of linoleic acid in an insect cell culture, said method comprising: growing an insect cell culture having a plurality of recombinant insect cells, wherein said insect cells or an ancestor of said insect cells were transformed with a vector comprising fungal DNA encoding a polypeptide which converts oleic acid to linoleic acid, wherein said DNA is operably associated with an expression control sequence functional in said insect cells, under conditions whereby said DNA is expressed, whereby linoleic acid is produced in said insect culture.

72. The method according to claim 71 wherein said fungal DNA is Mortierella DNA and said polypeptide is a Δ 12 desaturase.

73. The method according to claim 72 wherein Mortierella is of the species Mortierella alpina.

74. The method according to claim 71 wherein said conditions are inducible.

75. The method according to claim 71 wherein said fungal DNA comprises the DNA sequence depicted in SEQ ID NO:3.

76. The method according to claim 71 wherein the polypeptide comprises the polypeptide sequence depicted in SEQ ID NO:4.

77. A method for production of stearidonic acid in an insect cell culture, said method comprising: growing an insect cell culture having a plurality of recombinant insect cells, wherein said recombinant insect cells or ancestors of said recombinant insect cells were transformed with a vector comprising fungal

DNA encoding a polypeptide which converts γ-linolenic acid to stearidonic acid, wherein said DNA is operably associated with an expression control sequence functional in said recombinant insect cells, under conditions whereby said DNA is expressed, whereby stearidonic acid is produced from γ-linolenic acid in said insect cell culture.

78. The method of claim 77 wherein the sequence of said polypeptide comprises a sequence selected from the group consisting of residues 50-53, 39- 43, 172-176, 204-213 and 390-402 of SEQ ID NO:2.

79. A method for production of linoleic acid in an insect cell culture, said method comprising: growing an insect cell culture having a plurality of recombinant insect cells, wherein said recombinant insect cells or ancestors of said recombinant eukaryotic cells were transformed with a vector comprising fungal DNA encoding a polypeptide which converts oleic acid to linoleic acid, wherein said DNA is operably associated with an expression control sequence functional in said recombinant insect cells, under conditions whereby said DNA is expressed, whereby linoleic acid is produced from oleic acid in said insect cell culture.

80. A method for making gamma linolenic acid, said method comprising: growing a recombinant insect cell compromising a nucleotide sequence which encodes of functionally active Δ6 desaturase having the amino acid sequence depicted in SEQ ID NO:2, and at least one nucleic acid constmct comprising a nucleotide sequence which encodes a functionally active Δ12 desaturase having an amino acid sequence depicted in SEQ ID NO:4, wherein said nucleic acid constructs are operably associated with transcription control sequences functional in an insect cell under conditions whereby said nucleotide sequences are expressed, whereby gamma linolenic acid is produced in said insect cell.

81. A nutritional supplement comprising the stearidonic acid of claim 64.

82. A nutritional supplement comprising the linoleic acid of claim 71.